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ABSTRACT 
Protein kinases are important regulatory enzymes in signal transduction 
and in cell regulation. Understanding inhibition mechanisms of kinases is 
important for the further development of new therapies for cancer and 
inflammatory diseases. I have developed a statistical approach based on the 
Mantel test to find the relationship between the shapes of ATP binding 
sites and their affinities for inhibitors. My shape-based dendrogram shows 
clustering of the kinases based on similarity in shape. I investigate the 
pocket in terms of conservation of surrounding amino acids and atoms in 
order to identify the key determinants of ligand binding. I find that the 
most conserved regions are the main chain atoms in the hinge region and I 
show that the tetrahydropyran ring of staurosporine causes induced-fit of 
the glycine rich loop. I apply multiple linear regression to select distances 
measured between the distinctive parts of residues which correlate with the 
binding constants. This method allows me to understand the importance of 
the size of the gatekeeper residue and the closure between the first glycine 
of the GXGXXG motif and the aspartate of the DFG loop, which act 
together to promote tight binding to staurosporine. I also find that the 
greater the number of hydrogen bonds made by the kinase around the 
methylamine group of staurosporine, the tighter the binding to 
staurosporine. The website I have developed allows a better understanding 
of cross reactivity and may be useful for narrowing down the options for a 
synthetic strategy to design kinase inhibitors.  
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C h a p t e r  1   
INTRODUCTION 
1.1 Ligand promiscuity & selectivity 
Many diseases are characterised by dysregulation of biological pathways, 
which leads to change at the level of the individual cell, the tissue, and the 
whole organism. To restore the healthy state, some diseases can be cured 
by a small molecule drugs that inhibit a molecular target central to the 
disease mechanism (Zimmermann et al, 2007).  
Much effort has been spent in finding a compound with high binding 
affinity against a single target, a magic bullet. However, for some diseases 
which involve several pathways such as cancer, inhibition of a single target 
is not enough to restore the healthy state. A recent trend has been towards 
designing compounds that bind to multiple defined molecular targets, a 
magic shotgun. The most significant effort has been on tackling the 
resistance problem in HIV-1 anti-viral therapy and oncology (Hopkins et 
al, 2006). Several failures arising from targeting a single protein and 
successes from many selectively non-selective drugs have led to a 
paradigm shift from a magic bullet to a magic shotgun approach in 
therapeutic intervention in cancer, cardiovascular disease and CNS 
disorders (Frantz, 2005; Roth et al, 2004). Although side-effects of 
multitarget drugs are common, it has been argued that highly cross-reactive 
drugs might work better against drug resistance mutations based on the fact 
that such drugs normally have interactions with backbone groups and 
evolutionary conserved residues (Zhang et al, 2008).  
1 
Protein kinases are of considerable interest to the pharmaceutical industry 
because dysfunction often results in malignancy (Blume-Jensen & Hunter, 
2001; Cohen, 2002). This family of enzymes was chosen as my case study 
for the analysis of ligand promiscuity and selectivity because all share 
similar ATP binding sites. Indeed the success of several high affinity ATP-
mimetic drugs has made the design of selective inhibitors an attractive 
approach to useful therapeutics, particularly for oncology (Noble et al, 
2004). Although the structural conservation of the ATP binding site can 
lead to off-target ligand binding, kinase inhibitor design has become a 
promising way forward for discovery of useful therapeutic agents (Force et 
al, 2004).  
The major challenge for protein kinase inhibitor design is obtaining 
selectivity. In order to reduce the chances of undesirable side effects, 
potency is usually optimised against a target kinase while reducing off-
target activities including at other kinases. By understanding the ligand 
selectivity, cross reactivity might be removed by identifying a structural 
feature that promotes promiscuity and detecting non-conserved features 
that may enable paralog discrimination (Zhang et al, 2008).  
1.2 Protein kinase 
The human genome comprises more than 500 protein kinases (Manning et 
al, 2002), which are known to mediate most of signal transduction crucial 
to metabolism, cell proliferation and differentiation, membrane transport, 
and apoptosis. Protein kinases catalyse the transfer of a phosphate group, 
usually from ATP, to a hydroxyl group of a serine/threonine or tyrosine of 
a protein substrate. The molecular weight of protein kinase is about 30 kDa 
and the sequence length is usually 250-300 amino acids (Hanks et al, 
1988). Protein kinases share the same fold and similar ATP binding sites. 
However, they exhibit a variety of conformational states and regulatory 
mechanisms. 
2 
1.2.1 Regulatory Mechanisms 
“All active kinases are alike, but an inactive kinase is inactive after its own 
fashion” (Noble et al, 2004). Listed below are some examples of different 
regulatory mechanisms in the way kinases can be controlled. 
1.2.1.1 By phosphorylation of the activation loop  
 
Figure 1. The yellow segment in figure 1A is the activation segment. Activation 
segment is defined as the region between and including the DFG and APE tripeptide 
motifs in figure 1B (Nolen et al, 2004).  
Many kinases require activation by phosphorylation of the activation 
segment (Nolen et al, 2004). In the unphosphorylated state, the activation 
loop can adopt various conformations, for example allowing it to traverse 
the cleft between the N- and C-terminal lobes in IRK (Hubbard et al, 
1994). Upon phosphorylation, the activation loop moves away and allows 
the pocket to bind both the ATP and a peptide substrate (Hubbard, 1997).  
3 
1.2.1.2 Through interactions with regulatory subunits in response to 
second messenger  
Cyclic AMP dependent protein kinase (PKA) is one of the simplest kinases 
(Taylor et al, 2004) and the first protein kinase for which a crystal structure 
became available (Knighton et al, 1991). For these reasons, PKA are used 
as the reference molecule for several studies. PKA is active in the hetero-
tetrameric form. Without cyclic AMP, the two regulatory subunits of PKA 
inhibit the two catalytic subunits by binding to their active sites. Cyclic 
AMP binding to the regulatory subunits causes a conformational change 
and releases the activated catalytic subunit. 
1.2.1.3 By expression level of additional subunit  
Cell cycle progression in eukaryotic systems is tightly regulated by 
members of the CDK family (Nurse, 2002). The unmodified CDK cannot 
catalyse the phosphotransfer reaction, but a CDK can be activated at 
particular point in cell cycle upon binding to a cyclin (Morgan, 1997).  
1.2.1.4 By additional domains that inhibit kinase by autoregulatory 
processes 
c-Src was the first proto-oncogenic tyrosine kinase to be discovered 
(Stehelin et al, 1976). Intramolecular interaction of SH2 inhibits Src kinase 
by allowing the SH3 linker to bind to the surface of the N-terminal lobe 
and stabilising it in an inactive conformation (Xu et al, 1999). Ligand 
binding to SH2/SH3 or dephosphorylation leads to the release of the 
activated kinase domain (Blume-Jensen & Hunter, 2001). 
1.2.1.5 By pseudosubstrate segment which compete with its own 
substrate 
 The C-terminal domain of twitchin is called a pseudosubstrate because it 
competes directly with the substrate for access to the active site and 
4 
stabilises it in an inactive conformation (Hu et al, 1994; Huse & Kuriyan, 
2002). 
These mechanisms demonstrate that kinases can be regulated by various 
types of molecules and in a variety of binding states. Biologists have 
attempted to categorise kinases in several different ways. 
1.2.2 Classification  
The classic protein kinase phylogenetic tree was constructed on the basis of 
knowledge of sequence and biological function (Hanks et al, 1988). This 
thesis focuses on the relationship between the sequences and structures of 
kinases and inhibitor binding. Therefore, instead of classifying kinases by 
their function and sub-cellular location, e.g. receptor protein-tyrosine 
kinases (e.g. IRK, EGFR), cytoplasmic protein-tyrosine kinase (e.g. Src, 
JAKs, Abl), and serine-threonine kinases (e.g. CAMKs, CDK, MAPK, 
MEK, PKA, PKC), I refer to their type based on their sequence similarity. 
Kinases have been a topic of comprehensive classification (Cheek et al, 
2005; Scheeff & Bourne, 2005). The most widely used human protein 
kinase classification phylogenetic tree is constructed based on public and 
proprietary genomic, complementary DNA, and expressed sequence tag 
(EST) sequences. (Manning et al, 2002). According to the classification of 
Manning, the major kinase groups are as follows. 
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 Figure 2 The human kinase phylogenetic tree (Manning et al, 2002) 
1.2.2.1 TK (Tyrosine kinase) 
All members in this group phosphorylate tyrosine residues and their 
relationships can be observed from sequence similarity. Other dual 
specificity kinases (those which phosphorylate serine, threonine and 
tyrosine) are found scattered within other groups. 
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1.2.2.2 TKL (Tyrosine kinase-like) 
Although, the sequences of TKL family members are similar to those of 
the tyrosine kinase family, these enzymes form a distinct, closely related 
grouping. 
1.2.2.3 AGC  
This group contains PKA, PKG, PKC as members. Therefore, this group is 
called the AGC family. 
1.2.2.4 CAMK (Calcium/calmodulin-dependent protein kinase) 
Calcium/calmodulin regulated kinases and structurally related kinase 
families 
1.2.2.5 CKI (Casein kinase 1) 
1.2.2.6 CMGC  
This group contains CDK, MAPK, GSK3, CLK as members of the 
families. Therefore, it has this name from the initial letter of these kinases. 
1.2.2.7 STE (Homologs of yeast Sterile 7, 11, 20 kinases)  
This group comprises kinases in the MAP kinase cascade and homologs of 
yeast Ste7 (MAP2K), Ste11 (MAP3K) and Ste20 (MAP4K) kinases.  
1.2.2.8 RGC (Receptor Guanylate Cyclases) 
This group contains eukaryotic protein kinase domains that all appear to be 
catalytically inactive.  
1.2.2.9 AK (Atypical kinases) 
Atypical kinases consist of a relatively large family of important proteins 
such as PI3K, actin-fragmin kinase and choline kinase. They do not have 
significant sequence similarity to other eukaryotic kinase. Their structural 
character was studied in detail by Scheeff & Bourne (Scheeff & Bourne, 
2005). 
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1.2.2.10 Other 
Kinases that do not conform to any classification above. 
Since Manning et al. published their phylogenetic tree, several human 
kinome-wide studies have mapped structural coverage (Fedorov et al, 
2007; Marsden & Knapp, 2008) and binding interaction patterns (Fabian et 
al, 2005; Goldstein et al, 2008; Karaman et al, 2008) onto this human 
kinome tree. At the time of starting my PhD, the largest single source of 
publicly available kinase experimental binding data was the Supplementary 
Table 4 from Fabian et al. which had 119 kinases assayed against 20 
kinase inhibitors using T7-phage expression assays (Fabian et al, 2005). 
1.2.3 Architecture of the kinase fold 
 
Figure 3. Subdomains of kinases exemplified by the structure of PKA (Niedner et al, 
2006). 
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The kinase fold consists of the N-terminal lobe which contains mostly β-
sheets and the C-terminal lobe which contains mostly α-helices. For more 
detail analysis, the kinase fold can be divided further into subdomains. 
The descriptions of characters of each subdomain are taken from the 
structure walk-through of the protein kinase resource (Niedner et al, 2006) 
which follows the initial classification determined by Hanks & Hunter 
(Hanks & Hunter, 1995). 
Table 1. Subdomain boundaries in PKA and CDK2  
General Info  PKA CDK2 
Subdomain I 43-64 4-25 
Subdomain II  65-83 26-43 
Subdomain III  84-98 44-58 
Subdomain IV  99-113 59-73 
Subdomain V  114-137 74-98 
Subdomain VIA  138-160 99-121 
Subdomain VIB  161-177 122-138 
Subdomain VII  178-193 139-157 
Subdomain VIII  194-210 158-175 
Subdomain IX  211-240 176-209 
Subdomain X  241-260 210-254 
Subdomain XI  261-297 255-282 
 
1.2.3.1 Subdomain One:  
This subdomain contains the GXGXXGX motif, known as the glycine rich 
loop, which helps to anchor the ATP. 
1.2.3.2 Subdomain Two:  
There is an invariant lysine (Lys 72), which is shown to be very important 
for the catalytic activity of the enzyme  
1.2.3.3 Subdomain Three:  
This subdomain contains a prominent alpha helix (helix αC) (Huse & 
Kuriyan, 2002) and Asp 91 which form a salt-bridge with Lys 72. 
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1.2.3.4 Subdomain Four:  
It is the beta strand IV, no invariant residues in this subdomain. 
1.2.3.5 Subdomain Five:  
This subdomain acts as a bridge to connect between 2 lobes. The hinge 
region (residue 81-84 in CDK2) contains a set of hydrogen bond donor and 
acceptor sites that is required for potent inhibitor binding (Davies et al, 
2002). The hinge region begins with the gatekeeper residues, which form a 
hydrophobic pocket that surrounds the adenine ring. It contains Glu 127 
which binds to Arg of pseudosubstrate. 
1.2.3.6 Subdomain Six A:  
This large helix plays a mainly structural role. There is no invariant 
residue. 
1.2.3.7 Subdomain Six B:  
This subdomain comprises of two small strands with a loop between them. 
This loop is called the catalytic loop because Asp 166 in the loop is likely 
to form the catalytic base that accepts the proton from the protein 
substrate’s hydroxyl group.  
1.2.3.8 Subdomain Seven:  
This subdomain contains a conserved DFG motif. Asp 184 in the DFG 
motif helps in orienting the gamma phosphate of ATP by chelating the 
Mg2+ ions.  
1.2.3.9 Subdomain Eight:  
This subdomain consists of the activation loop, which is used for substrate 
recognition and stabilisation. It contains a highly conserved APE motif. 
Many protein kinases become activated by phosphorylation of residues in 
this subdomain.  
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1.2.3.10 Subdomain Nine:  
This subdomain stabilises the catalytic loop and plays a role in pseudo-
substrate recognition. 
1.2.3.11 Subdomain Ten:  
This is a small alpha helix with unknown function. 
1.2.3.12 Subdomain Eleven:  
This marks the C-terminal boundary of the kinase domain from the rest of 
the protein. 
1.2.4 The ATP binding site 
According to the pharmacophore model for tyrosine kinases (Traxler & 
Furet, 1999), the ATP binding site can be divided into 5 regions which 
have distinct chemical environments (Figure 4). 
 
Figure 4. Protein kinase pharmacophore (Traxler & Furet, 1999). This residue 
numbering is for cyclic AMP dependent protein kinase (PKA). The GXGXXGX motif 
is the loop above the oxygen of ribose. 
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1.2.4.1 Adenine region 
This is the region where all ATP-competitive kinase inhibitors bind. The 
major interaction of adenine in this hydrophobic pocket is the hydrogen 
bond donor acceptor system through the backbone carbonyl of Glu 121 and 
backbone NH of Val 123 in PKA. Although the backbone carbonyl of 
residue 123 is not used for ATP binding, it can serve as a hydrogen bond 
acceptor for some inhibitors, such as olomoucine (Schulze-Gahmen et al, 
1995). 
1.2.4.2 Sugar pocket 
This region is often exploited to accommodate solubilising groups because 
of its hydrophilic character. It is not highly conserved and can be used to 
direct selectivity (Keri et al, 2006). 
1.2.4.3 Hydrophobic region I or hydrophilic backpocket 
This region is the space extending from the lone pair nitrogen of ATP. It is 
not conserved and has been used to gain affinity as well as selectivity for 
several potent inhibitors of serine/threonine and tyrosine kinase (Keri et al, 
2006). Access to this pocket is controlled by an amino acid residue, which 
is equivalent to residue 120 in PKA, called the gatekeeper (Liu et al, 1999). 
There is evidence that the selectivity of pyrazolopyrimidines is controlled 
by the size of this amino acid (Schindler et al, 1999). Most tyrosine kinases 
have a small gatekeeper residue (threonine or valine), which makes them 
more sensitive to these drugs than most serine/threonine kinases, which 
have a larger gatekeeper residue (methionine or isoleucine). A mutant of 
tyrosine kinase Src with modified gatekeeper residue (T338I) has broad 
inhibitor resistance (Apsel et al, 2008). 
1.2.4.4 Hydrophobic region II or surface exposed front area 
This region is a hydrophobic slot open to solvent, which is not used by 
ATP (Traxler & Furet, 1999).  
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1.2.4.5 Phosphate binding region 
This region has high solvent exposure and seems unimportant for binding 
affinity. It can be used to gain selectivity (Traxler & Furet, 1999).  
Many more small pockets have been identified for the analysis of selective 
kinase inhibitors (Liao, 2007). 
1.3 Binding site studies 
There is evidence that high affinity targets sometimes have similar residues 
at positions important for binding of a given kinase inhibitor, although 
others with similar residues at these important positions can be insensitive 
to such inhibitors, probably due to conformational differences (Sheinerman 
et al, 2005). Therefore, understanding kinase selectivity cannot be achieved 
only through the analysis of sequences but must also consider three-
dimensional structures.  
Although biomolecules are in motion, we often treat them as static objects 
and determine their shapes by their surfaces. At the molecular level, the 
solid sphere representation is normally used to define shape (Morris et al, 
2005). For relating biological activities between drug-like molecules and 
their molecular targets, the shape of the pocket is the most discriminating 
factor (Ballester & Richards, 2007).  
Cavity detection methods have been divided into those that depend on 
energetic criteria and geometry criteria. An example of energetic-based 
detection is Qsitefinder (Laurie & Jackson, 2005) which calculates the van 
der Waals interaction energy of a methyl probe with the protein. The 
probes, which have favourable interaction energies, are obtained and a 
cluster of these probes is ranked according to interaction energy. This 
method has proven efficient in the detection of binding sites.  
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The geometry-based cavity detection methods have been divided further 
into volumetric based and surface based. Based on the description by 
Nayal and Honig, “Volumetric methods aim to identify spaces in the 
vicinity of the protein sequestered by protruding protein atoms, while 
surface-based approaches locate surface cavities by an analysis of the 
geometry of the molecular surface itself” (Nayal & Honig, 2006).  
Early solvent accessible surface methods were developed by Lee and 
Richards (Lee & Richards, 1971) and later improved by Connolly 
(Connolly, 1983). The algorithm employed a sphere of solvent molecule to 
roll over the protein to generate a smooth surface. Surface-based 
approaches have been very useful for visualising shape-complementarity 
and protein-protein interfaces. Many site comparisons use volumetric-
based methods, which can be divided further as to whether or not they rely 
on the 'grid method'.  
If the protein is embedded in a 3D grid, points, which are not overlapped 
by protein atoms, are detected and then certain criteria are applied to judge 
whether they are parts of the pocket. Examples of programs that use the 
grid volumetric-based method are Ligsite (Hendlich et al, 1997) used in 
Cavbase (Kuhn et al, 2006) and VOIDOO (Kleywegt & Jones, 1994). If 
the protein is not embedded in a 3D grid, surfaces are either identified by 
Voronoi tessellations or sphere clusters such as SURFNET (Laskowski, 
1995) used in calculating real spherical harmonic expansion coefficients 
which can be used as 3D shape descriptors (Karaman et al, 2008; Morris et 
al, 2005 ).  
In this thesis, I describe surfaces defined by volumetric-based geometric 
criteria, either through frequently occurring atoms on a grid (Chapter 2) or 
at representative points without a grid (Chapter 3), in order to describe the 
overall ‘shape’ of the kinase pocket.  
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Due to their well-defined shapes and the pharmaceutical importance of 
protein kinases, ATP binding pockets have been used as case studies for 
intensive binding site analyses in several papers. In 2002, Naumann and 
Matter classified kinases based on similarity in protein-ligand interaction 
features in 26 X-ray structures from 6 kinase families. They used GRID 
force-field probes (i.e. hydrophobic probe, sp2 carbonyl oxygen probe, 
neutral flat NH probe) with 1 Å spacing to derive binding site information 
in the form of interaction energies on a GRID molecular interaction field. 
After that, the data matrix was scaled and principal component analysis 
was used to cluster kinases with common interaction patterns. The 
approach can classify kinase-binding sites into subfamilies and identify 
favourable interactions that are characteristic for each class. 
In 2007, Kuhn et al. used Cavbase to classify protein kinases from 258  
X-ray structures in 48 subfamilies (Kuhn et al, 2007). Cavbase uses Ligsite 
which generates grids with a 0.5 Å spacing to detect buried cavities. If 
there are atoms in any amino acid that are closer than 1.1 Å to a surface 
point, such atoms will be used as a pseudo centre to represent the chemical 
property of that region. Common substructures are identified by the clique 
algorithm (Bron & Kerbosch, 1973). The closest matches are compared by 
determining the overlap between surface patches and pseudo centres. 
Similarity matrices generated from various clustering methods were used 
as inputs for principal component analysis, enabling the detection of cross-
reactivity between various kinases.  
In 2009, Kinnings and Jackson used a geometric hashing algorithm to 
compare binding sites based on atom-atom similarity in an all-against-all 
manner amongst 354 crystal structures from 75 different kinases (Kinnings 
& Jackson, 2009). Their geometric hashing procedures can be divided into 
a pre-processing stage and a recognition stage. In the pre-processing stage, 
distance features between all atom pairs of the model molecules are 
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calculated and converted into a hash table. In the recognition stage, the 
same representations are calculated for the target molecule and this 
information can be used to access the hash table. If the pattern of the 
second matches that of the first by more than a certain score, a rigid body 
transformation is applied to expand the number of matching points (Via et 
al, 2000). Similarity scores were clustered and comparisons were made 
between the sequence-based and binding site based classifications. The 
authors found that many clusters can be generated from related kinases, 
and hence structural similarity is sufficient for the classification of the 
highly conserved ATP binding site in kinases. 
1.4 Quantitative Structure-Activity Relationship (QSAR) 
This methodology has been developed following the idea of Crum-Brown 
and Fraser who proposed that the physiological action of a substance 
relates to its chemical constitution (Crum-Brown & Fraser, 1868) and 
independent reports which suggested that there is a linear relationship 
between the depressant action of organic compounds and their oil/water 
partition coefficient (Meyer, 1899; Overton, 1901). Later, Hammett 
defined a linear free energy relationship between the reactivity and 
electronic properties (σ) of aromatic substituents with their equilibrium 
constants (Hammett, 1935). This relationship formed the mechanistic basis 
for the development of the linear Hansch equation and then a more 
successful parabolic equation as shown below (Hansch, 1969; Hansch & 
Fujita, 1964). 
Equation 1 
log (1/C) = a(log P)2 +b(log P)+cσ+…+k; 
where C is the molar concentration that produces a biological effect, P is 
the octanol/water partition coefficient and σ is the electronic Hammett 
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constant. This improved equation which combines a parabolic model with 
various physicochemical properties allows for the description of structure-
activity relationships that cannot be correlated with a single linear term. 
A true structure-activity relationship model is the Free-Wilson approach 
(Kubinyi, 1993). Free and Wilson (Free & Wilson, 1964) described in the 
equation that biological activity can be defined as a contribution of the 
parent molecule (μ) and the group contribution of all structural features 
attached to that parent molecule (ai) below. 
Equation 2 
log (1/C) = Σai + μ 
A combination of the Hansch and Free-Wilson equations leads to the 
mixed approach below: 
Equation 3 
log (1/C) = a(log P)2 + b log P + cσ + … + Σai + k 
This mixed approach equation is a more powerful tool for large and 
structurally diverse quantitative structure activity relationships (Kubinyi, 
1993). More advanced QSAR methods make analogies of how a binding 
site feels the electrostatic potential of the ligand by mapping molecular 
fields calculated from atomic probes onto three-dimensional grids which 
include several thousands of points as descriptors (Kubinyi, 1998). This 
thesis explores the idea of relating biological activity with distance 
parameters using multiple linear regression in a similar manner to the 
QSAR method. 
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1.5 Fragment Recognition 
After investigating cross-reactivity features, I explore the possibility of 
designing new staurosporine derivatives by utilising knowledge of 
fragment environments gained by using a web tool to assist in molecular 
design. 
The fragment approach to molecular recognition is a very promising field 
in drug design (Fattori, 2004). A computational approach to modify the 
functional groups of compounds with topologically different scaffolds that 
exert the same biological activity, known as bioisosteric replacement or 
scaffold hopping, has also been the topic of several discussions (Zhao, 
2007).  
Several studies have searched for bioisosteres, functional groups that are 
structurally different but can form similar intermolecular interactions. A 
change of chemical template may give rise to a compound with better 
solubility, enhanced pharmacokinetic properties, improved binding 
affinity, and may lead to a novel compound which is patentable (Böhm et 
al, 2004). Some scaffolds have been shown to be active in several target 
proteins, so providing opportunities for use in different therapeutic areas. 
On the other hand, some scaffolds specifically target certain drug target 
families and can be used as molecular anchors for functional decoration 
(Muller, 2003). 
The key methods in scaffold hopping include shape matching, 
pharmacophore searching, fragment replacement and similarity searching 
(Böhm et al, 2004). These methods differ in the way similarities between 
bioisosteric groups are determined (Wagener, 2006). Even though common 
chemical replacements in drug-like compounds have already been 
described (Sheridan, 2002) and a ring replacement database has been 
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constructed (Lewell et al, 2003), the chemical environments of functional 
groups within protein structures have not yet been considered. 
One interesting study exploited a set of crystal structures of proteins 
harbouring different ligands. Bioisosteres were identified from pairs of 
substructural features with high volume overlap from an overlay of the 
structures (Kennewell et al, 2006). Another study which used Relibase to 
find interacting functional groups and their preferred interaction geometries 
also pinpointed the importance of the chemical environment in the protein 
for identifying bioisosteres (Bergner et al, 2001). Such information about 
which set of atoms/residues interact with a certain fragment is not 
systematically incorporated in the available public databases. 
Bemis analysed a set of 5120 drug molecules from the Comprehensive 
Medicinal Chemistry database and found that 50% of the drugs were 
derived from only 32 molecular frameworks (Bemis & Murcko, 1996). 
Similarly, Ertl analysed a set of 3 million compounds and identified the 50 
most common substituents (Ertl, 2003). These sets of fragments give an 
estimation of the scale of the problem and can be a good starting point for a 
systematic analysis of the underlying structural basis of fragment 
recognition. If the Protein Data Bank contains enough molecular varieties, 
it might be possible to achieve bottom-up molecular design by linking 
together fragments that can fit into known chemical environment. 
1.6 Thesis objectives  
My aim was to develop computational approaches that could account for 
the specificity and discrimination of inhibitors for kinases and that might 
contribute to a general understanding of molecular recognition in other 
systems. Using the grid method, I developed a procedure to observe the 
region in the ATP-binding pocket which causes cross-reactivity among 
kinases. A method was developed that can compare the shapes of kinase 
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pockets by using distance matrices measured from representative atoms. 
From these analyses, I rationalised how features with the most variable 
positions in the binding site affect binding affinity by using a multiple 
linear regression method. Lastly, I developed a tool to assist in the 
understanding of ligand binding and in minimising the choices for 
synthetic strategies to design specific kinase inhibitors. 
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C h a p t e r  2  
2 CONSERVED ATOMS AND RESIDUES IN THE ATP 
BINDING SITE 
The conservation of atoms and residues in the active sites of kinases is 
analysed by superposing the structures of complexes with the same ligand 
and the entities that most often retain their position are observed. The 
neighbouring atoms surrounding the universal kinase inhibitor 
staurosporine have a higher degree of conservation in position than those 
surrounding adenosine complexes, which is consistent with the hypothesis 
that the rigidity of staurosporine can fix some parts of the active site in 
particular positions. The representation at residue level brings us closer to 
unraveling kinase specificity. It demonstrates that the Cα of the first 
glycine of the glycine-rich loop (GXGXXG) is recruited towards the ether 
oxygen of the ribose upon staurosporine binding (found in 75% of the non-
redundant staurosporine complexes). Therefore, the active site can 
contract or expand to accommodate a larger ligand, and staurosporine 
leads to an induced-fit in the pocket of the kinases. 
2.1  Introduction 
The first phase of my research focused on an analysis of ATP binding sites 
in protein kinases because of their importance in chemotherapy and the 
availability of X-ray structures in the Protein Data Bank. I try to minimise 
the problems of conformational change, protein flexibility and electrostatic 
potential by focusing mainly on structures of protein kinases which bind to 
either adenosine derivatives or to a universal kinase inhibitor called 
staurosporine. This molecule is quite rigid, and only the parts that can 
make strongly electrostatic interactions mimic those of ATP. Hence, it 
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should constrain the active site of those kinases that it binds sufficiently 
well for a comparison of surrounding atoms and binding affinities. I 
hypothesize that atoms that remain conserved both in atom type and 
position for complexes with the same ligand maintain their structural role 
to satisfy optimal interaction with the ligand. Therefore, surrounding 
kinase atoms which share a conserved position in both ATP and 
staurosporine complexes may be generally required for the binding of 
kinase ligands.  
The idea of this approach to study position-specific interactions originated 
from image processing in electron microscopy where large numbers of 
images are superposed in order to intensify the true signal relative to the 
background noise. The algorithm developed constructs a grid box around 
the rigid part of superposed ligand and collects data points in four 
dimensions, i.e. residue or atom types, and x, y, z coordinates, from the 
non-redundant protein kinase structures. The final representation is 
obtained by converting the image to the form of a PDB file, in which 
signal-to-noise ratio thresholds can be altered in order to optimise 
visualization. The approach is encoded in new software called SIMFONEE 
(specificity implication from frequently occurring neighbouring entities). 
2.2 Methods 
2.2.1 Dataset 
The structures of protein kinases were selected from the MSDlite Database 
(Golovin et al, 2004) to allow queries from the Gene Ontology 
identification number (GO:0004672), which gives a precise identification 
for ‘protein kinase activity’. Structures with resolutions better than 3.0 Å 
and containing either staurosporine or adenosine phosphate moieties 
comprised the initial data set. Non-redundant PDB chains were selected 
manually to cover all staurosporine and adenine phosphate complexes. The 
structures of 20 staurosporine-kinase complexes were superposed on the 
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indolocarbazole moiety from staurosporine in PDB ID 1stc (Prade et al, 
1997) in order to compare them with the structures of 24 adenosine 
phosphate-kinase complexes, which were superposed on the adenine ring 
from ATP in PDB ID 1atp (Zheng et al, 1993). The chosen structures are 
listed in Table 2, along with details of their quality and the complex 
crystallised in Appendix A. 
Table 2. PDB code and the chain used in position-specific study 
LIGAND LIGAND 
CODE 
PDB CODE FOLLOWED BY CHAIN 
IDENTIFIER 
Staurosporine STU 1AQ10, 1BYGA, 1NVRA, 1NXKA, 1OKYA, 1Q3DA, 
1QPDA, 1SM2A, 1STCE, 1U59A, 1XBCA, 1XJDA, 
1YHSA, 2CLQA, 2DQ7X, 1WVYA, 2ITWA, 2OICA, 
2GCDA, 2HW7A 
ATP 1ATPE, 1OL6A, 1QL6A, 1S9JA, 1QMZ 
1U5RA, 1ZYDA, 2BIYA 
ANP 1DAWA, 1IR3A, 1J1BA, 1JKLA, 1LP4A, 1MQBA, 
1O6KA, 1PJKA, 1QPCA, 1YXTA, 2A19B, 1Q99 
ACP 1K3AA, 1O6YA, 1U54B 
Adenosine 
phosphate 
AMP 2IVTA 
 
2.2.2 Classification of neighbouring atom types 
The position-specific interactions were considered at two-levels: the atom 
type and the residue type. For atom matrices, atoms in the PDB file were 
assigned an atom type according to the simplified approach used in the 
AMBER force field, which has been developed specially for molecular 
mechanics calculations of proteins and nucleic acids (Cornell, 1995) 
(Supporting Information 1). The atom type categorisation is based on the 
assumption that atoms around the side chains that have the same functional 
group can be classified as the same atom type, e.g. carboxylate oxygens of 
Asp and Glu have sp2-oxygen atom types. By using this approach, we can 
capture similar interactions in the pocket made by the same part of the 
ligand. The available atom types in this classification program are 
described below. 
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• Carbons  
1. CT: any sp3 carbon 
2. C: any carbonyl sp2 carbon  
3. CA: any aromatic sp2 carbon and Cε of Arg 
4. CH: all of histidine’s aromatic carbons except for CD2 (i.e. sp2 
aromatic carbon in 5-membered ring with one substituent and next 
to nitrogen, or next to carbon and lone pair nitrogen, or next to two 
nitrogens) 
5. CW: tryptophan’s carbon in connection with the 5-membered ring 
(i.e. sp2 aromatic in 5-membered ring next to carbon and NH, or at 
junction of 5- and 6-membered rings, or next to two carbons, or sp2 
junction between 5- and 6-membered rings and bonded to CH and 
NH) 
6. CX: any other unidentified carbon including carbon from the 
bound ligand 
• Nitrogens 
7. N : sp2 nitrogen in amides  
8. NC : sp2 nitrogen in aromatic rings (sp2 nitrogen with hydrogen 
attached, sp2 nitrogen in 5-membered or 6-membered ring with 
lone pair electrons)  
9. N2 : sp2 nitrogen of aromatic amines  
10. N3 : sp3 nitrogen 
11. NX: any other unidentified nitrogen including nitrogen from the 
bound ligand 
• Oxygens 
12. OH : sp3 oxygen in alcohols, tyrosine, and protonated carboxylic 
acids 
13. O: sp2 oxygen in amides  
14. O2 : sp2 oxygen in anionic acids 
15. OW: oxygen in water 
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16. OX: any other unidentified oxygen 
• Sulphur 
17. SH: cysteine sulphur 
18. S: methionine sulphur  
19. SX: any other unidentified sulphur 
• Phosphorous 
20. P: phosphorus in phosphates 
• Halogens 
21. X: F, Cl, Br, I  
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Table 3. Classification of amino acid atoms  
   Atom     Type    Atom     Type    Atom     Type 
Glycine N  N Aspartate N  N Histidine N  N 
Glycine CA  CT Aspartate CA  CT Histidine CA  CT 
Glycine C  C Aspartate C  C Histidine C  C 
Glycine O   O Aspartate O  O Histidine O  O 
Alanine N  N Aspartate CB  CT Histidine CB  CT 
Alanine CA  CT Aspartate CG  C Histidine CG  CH 
Alanine C  C Aspartate OD   O2 Histidine ND1  NC 
Alanine O  O Asparagine N  N Histidine (HE/+) CD2  CW 
Alanine CB   CT Asparagine CA  CT Histidine (HD) CD2  CH 
Valine N  N Asparagine C  C Histidine CE1  CH 
Valine CA  CT Asparagine O  O Histidine NE2   NC 
Valine C  C Asparagine CB  CT Phenylalanine N  N 
Valine O  O Asparagine CG  C Phenylalanine CA  CT 
Valine CB  CT Asparagine OD1  O Phenylalanine C  C 
Valine CG   CT Asparagine ND2   N Phenylalanine O  O 
Leucine N  N Glutamate N  N Phenylalanine CB  CT 
Leucine CA  CT Glutamate CA  CT Phenylalanine CG  CA 
Leucine C  C Glutamate C  C Phenylalanine CD  CA 
Leucine O  O Glutamate O  O Phenylalanine CE  CA 
Leucine CB  CT Glutamate CB  CT Phenylalanine CZ   CA 
Leucine CG  CT Glutamate CG  CT Tyrosine N  N 
Leucine CD   CT Glutamate CD  C Tyrosine CA  CT 
Isoleucine N  N Glutamate OE   O2 Tyrosine C  C 
Isoleucine CA  CT Glutamine N  N Tyrosine O  O 
Isoleucine C  C Glutamine CA  CT Tyrosine CB  CT 
Isoleucine O  O Glutamine C  C Tyrosine CG  CA 
Isoleucine CB  CT Glutamine O  O Tyrosine CD  CA 
Isoleucine CG1  CT Glutamine CB  CT Tyrosine CE  CA 
Isoleucine CG2  CT Glutamine CG  CT Tyrosine CZ  C 
Isoleucine CD   CT Glutamine CD  C Tyrosine OH   OH 
Serine N  N Glutamine OE1  O Tryptophan N  N 
Serine CA  CT Glutamine NE2   N Tryptophan CA  CT 
Serine C  C Methionine N  N Tryptophan C  C 
Serine O  O Methionine CA  CT Tryptophan O  O 
Serine CB  CT Methionine C  C Tryptophan CB  CT 
Serine OG   OH Methionine O  O Tryptophan CG  CW 
Threonine N  N Methionine CB  CT Tryptophan CD1  CW 
Threonine CA  CT Methionine CG  CT Tryptophan CD2  CW 
Threonine C  C Methionine SD  S Tryptophan NE1  NC 
Threonine O  O Methionine CE   CT Tryptophan CE2  CW 
Threonine CB  CT Lysine N  N Tryptophan CE3  CA 
Threonine OG1  OH Lysine CA  CT Tryptophan CZ2  CA 
Threonine CG2   CT Lysine C  C Tryptophan CZ3  CA 
Cysteine N  N Lysine O  O Tryptophan CH2   CA 
Cysteine CA  CT Lysine CB  CT Arginine NE  N2 
Cysteine C  C Lysine CG  CT Arginine CZ  CA 
Cysteine O  O Lysine CD  CT Arginine NH   N2 
Cysteine CB  CT Lysine CE  CT 
Cysteine SG   SH Lysine NZ   N3 
Proline N  N Arginine N  N 
Proline CA  CT Arginine CA  CT 
Proline C  C Arginine C  C 
Proline O  O Arginine O  O 
Proline CB  CT Arginine CB  CT 
Proline CG  CT Arginine CG  CT 
Proline CD   CT Arginine CD  CT 
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2.2.3 Classification of neighbouring residues types 
Residue classification in SIMFONEE includes 20 amino acids and water, 
which comprises the 21 residue types. Cystine is omitted because it occurs 
rarely inside the cell. Each amino acid residue is simplified to one point at 
the position of its representative atom located at a distinctive part near the 
end of the side chain. The coordinate of this centre of the residue is a 
representative position of the whole amino acid at the residue level. 
Table 4. Representative atoms of the 20 amino acids 
GLY  CA ALA  CB SER  OG CYS  SG 
 
   
VAL  CB LEU  CG ILE  CG1 THR  CB 
 
 
 
 
ASP  CG GLU  CD ASN  CG GLN  CD 
    
MET  SD LYS  CE ARG  CZ PRO  CG 
 
 
  
HIS  NE2, PHE  CZ TYR  CZ TRP  CD2 
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2.2.4 Algorithm of the software SIMFONEE 
This software written in Perl derives structure-based information from 
crystal structures of protein kinases. I have developed a computer program 
to extract generalized features that are frequently found in protein kinase 
structures by constructing a 4-dimensional grid to capture different entities 
that are conserved in atomic position on structure superposition of 
staurosporine complexes. The grid collects occupancies from atoms from 
superposed structures that satisfy the four criteria, i.e. x,y,z coordinates and 
atom or residue type.  
2.2.4.1 PDB file preparation 
The input to this program is a list of PDB chain codes. The program 
downloads the PDB file from a local repository and extracts only the 
structure from the specified chain, or takes the whole structure if it is 
defined as having chain code 0. This structure is processed by program 
Moleman2 in order to set all the water molecules to chain ‘W’, and all the 
ligands to chain ‘Q’. Proteins without chain letters are reassigned by the 
program PDBset to have chain letter Z. The objective of this process is to 
avoid ambiguities arising from having several atoms with the same 
sequence number and the same chain which may confuse the classification 
and superposition programs. The processed structures are written to a new 
filename with a 4 letter PDB code and one extra-letter to identify the 
selected chain. 
2.2.4.2 Superposition on the ligand 
In order to allow visualization in the same coordination system, all output 
files should be in the same orientation. Therefore, all other PDB chains are 
superposed onto the same set of templates and kept in separate directories 
according to the template used for superposition. The catalytic subunit of 
bovine cyclic 3'- 5' adenosine monophosphate-dependent protein kinase 
(PKA) in complex with staurosporine, PDB ID 1stc (Prade et al, 1997), is 
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used as the template and the reference residue nomenclature in this study 
because PKA is the first protein kinase for which a crystal structure 
became available and its residue nomenclature is widely used in kinase 
analyses. Therefore, the several templates for superposition are oriented 
according to this structure in order to refer to its residue numbers. The 
staurosporine template was taken from residue STO of the staurosporine in 
PKA (1stcE). Similarly, the template for the adenosine ring was taken from 
residue ATP of PKA structure 1atp.pdb after the active site had been 
superposed onto 1stc.pdb so that the neighbouring environment observed 
from both templates are in the same frame of reference as shown in Figure 
5. 
 
Figure 5. Staurosporine (carbons in orange stick) in complex with PKA, with the main 
chain in the same orientation as that found in the complex of PKA with ATP (carbons in 
green sticks) 
For every input PDB file, SIMFONEE scans for the ligand centre and 
extracts all neighbouring atoms within a 20 Å radius from the centre of the 
ligand. Then it superposes the ligand sphere onto the appropriate ligand 
template using the CCP4 program LSQKAB.  
2.2.4.3 Superposition on the kinase subdomain 
Because the N-terminal lobes of protein kinases are quite plastic, the 
frequencies of residues from this domain obtained from main chain 
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superposition would fluctuate in accordance with the overall conformation 
of the protein. Partial secondary structures of the protein PDB ID 1b39 
(chain A) are used as the template for superposition to observe conserved 
residues when there are large conformational changes between the 
domains. The template for the N-terminal lobe superposition includes a 
major part of the β-sheets down to the hinge region and helix αc (Figure 6), 
whereas the catalytic loop and four other helices are used as the template 
for C-terminal lobe superposition (Figure 7). 
 
Figure 6. The N-terminal template (left) and superposition of the N-terminal domain 
(right) 
 
Figure 7. The C-terminal template (left) and superposition of the C-terminal domain 
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2.2.4.4 Counting frequently occurring atoms and residues 
The arrays of 4 dimensions were created for collecting the entities 
neighbouring the adenosine ring and staurosporine. Each block of the 
ligand array is defined by [type][x][y][z] and acts as a large bin to store 
occupancies from every surrounding atom which have the four parameters 
defined, i.e. type and x, y, and z coordinates. The entity is classified based 
on the either atom type or residue type as described earlier for the 
classification of the entities. The last three parameters describe the 
estimated position of the points at 1 Å step size by using the rounded 
integer of the coordinates x, y and z.  
 
Figure 8. Illustration of filling the occupancies of the matrix identified by 4 parameters: 
[types][x][y][z]. 
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2.2.4.5 Writing output by modifying the PDB format file and 
visualisation in Pymol 
For the atomic level, the grid was stored in PDB file format and 
occupancies of boxes were contoured using the color_b module of the 
program Pymol (DeLano, 2002) to obtain a transparent surface with the 
intensity of the colour corresponding to the frequency with which the grid 
boxes are populated. To visualise only the top rank entities, the grid can be 
displayed at different cut-off values. The array of frequently occurring 
atoms can also be displayed as a non-bonded sphere (Figure 9) with a label 
corresponding to the frequency with which the array is populated.  
 
    Carbon            Nitrogen          Oxygen           Sulphur          Phosphorus         Others        
Figure 9. Non-bonded sphere representation for neighbouring atoms in the array 
For the residue level, relative positions of neighbouring residues for 
different ligands were observed by superposing the majority of the residue 
clusters surrounding adenine and staurosporine, and then comparing the 
positions of these clusters for adenine complexes and staurosporine 
complexes. The staurosporine complexes are displayed with large sticks 
and adenosine phosphate complexes are displayed with small sticks, so that 
the relative positions of residue clusters can be compared. For visualising 
the cluster, a bond is drawn automatically when two atoms come closer 
than about 2 Å so the cluster can be easily found. Colours of frequently 
occurring residues are assigned according to the type of the amino acid 
found in the array. (Figures 10 & 11). 
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Figure 10. Water and amino acid neighbouring residues in dot representation 
 
Figure 11. Water and amino acid residue in sphere representation. These atoms are used 
to represent the centres of the residues.  
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2.3 Results & Discussion 
The staurosporine molecule is quite rigid as it contains very few rotatable 
bonds; hence we may observe interaction partners that are position-specific 
by superposing the kinases onto its lactam and indolocarbazole rings (20 
structures of staurosporine complexes). In a similar manner interactions 
around the adenosine phosphate complexes can be compared by 
superposing the non-redundant kinase structures onto the adenine ring (24 
structures of adenine-containing complexes). The conserved atomic 
environment can be found by observing the frequently occurring atoms at a 
particular location defined by a 1 Å grid box  
2.3.1 The frequently occurring entities obtained by superposing ligand 
I observe that some clusters of amino acids preserve their functional groups 
in most of the staurosporine and the adenine complexes, for instance the 
side chains of Glu and Asp of the salt-bridges which flank each side of the 
pocket, the residues that are equivalent to Ala 70 in PKA which acts as the 
ceiling of the cleft, and Gly 50 which interacts with the ether oxygen of the 
sugar moiety (Figures 12 & 13). For the adenine complex, the most 
conserved part is the protein kinase main chain in the hinge region which 
interacts with the amine group of the adenine ring (Figure 12).  
 
Figure 12. Stereo image illustrating frequently occurring neighbouring environment of 
adenosine ring at atomic level (spheres) and residue level (dots). The colour of atoms 
shown in Figure 9 and the colour of residues are shown in Figure 10. 
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For the staurosporine complex, the most conserved parts are the main chain 
of the hinge region, which interacts with the lactam oxygen, and the α-
carbon of the first glycine of the GXGXXG motif, which interacts with the 
sugar moiety (Figure 13).  
 
Figure 13. Stereo image illustrating frequently occurring neighbouring environment of 
staurosporine at atomic level (spheres) and residue level (dots). The colours of atoms are 
shown in Figure 9 and those of residues in Figure 10. 
2.3.2 Comparison of flexibility of the pocket 
The resulting atomic level matrices suggest that for both adenine and 
staurosporine ligand complexes (Figures 14 & 15), the main chain atoms 
make the most conserved interactions in terms of type and position, which 
explains why staurosporine, mimicking ATP, can bind to most of the 
kinases. 
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 Figure 14. The hinge region (left) of the adenine phosphate binding complexes is the 
most conserved region. The colour of the surface is related to the occupancy of atoms in 
the array. The atom types (CT, N, C, O) are defined in Section 2.2.2. 
 
Figure 15. The maximum percent of conservation of frequently occurring neighbouring 
atoms in staurosporine complex (75%) shows that staurosporine pocket is more rigid 
than that of ATP. The atom types (CT, N, C, O) are defined in Section 2.2.2. 
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The conserved neighbouring atoms of ATP are more variable in position 
than those of staurosporine (37.5-58% conservation in Figure 14 versus 50-
75% in Figure 15). This supports the idea that the two ligands require a 
different degree of flexibility within the active site of the kinase. The 
greater number of rotatable bonds in the adenosine phosphate results in 
lower degree of conservation of neighbouring atoms in these complexes 
than in staurosporine complexes. Since the ribose moiety of the adenosine 
complex can adopt several conformations, the frequently occurring atoms 
fall in several grid boxes.  
2.3.3 Amino acid movement and substitution in the pocket 
The residue arrays serve to complement the pictorial representations of the 
atomic environment. For most of the residues, I chose the penultimate 
atoms of the side chain to represent the identities and the positions of the 
residues (Table 4). In this way, residues with a similar functional group at 
the end of the side chain in different kinases can be captured as points at a 
similar location in the superposed structures. For instance, Cβ of valine and 
Cγ of leucine at the active sites occupy the same or close-by grid boxes in 
the superposed structures. Several clusters of amino acids are seen to have 
moved, leading to contraction and expansion of the residues in the pocket 
to accommodate staurosporine (Figure 16).  
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Figure 16. Contraction (blue arrows) and expansion (pink arrows) of the staurosporine 
pocket found when the residues in the environment of staurosporine (white large sticks) 
are superposed on those of adenine phosphates (yellow thin sticks). 
The ends of some similar hydrophobic side chains e.g. Cys and Met, or 
Ala, Val and Leu, which surround the planar indolocarbazole ring, have 
equivalent positions implying that these amino acids perform the same 
function in that part of the active site. On the other hand, the amino acids 
that make contact around the methyl amino and methoxy groups of 
staurosporine demonstrate that remarkably different functional groups can 
occupy the same position and carry out the same structural role.  
2.3.4 Induced fit caused by staurosporine 
Seventy five percent (15 out of 20 staurosporine bound structures) of the 
main chain alpha carbons from the first glycine of the glycine rich loop, 
Gly 50, fall in the same 1 Å grid-box (Figure 17). On the other hand, these 
atoms are distributed within a rhombohedron-shaped volume (see Figure 
18) when superposed on the adenine ring.   
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Figure 17. The first glycine of the GXGXXGX motif (Gly 50) is found in the same grid 
box in fifteen from twenty staurosporine binding structures. The residue that is most 
conserved in position during N-terminal domain superposition is Ala 70. 
 
Figure 18. The first glycine (Gly 50) of the GXGXXGX motif can move freely in a 
rhombohedron-shaped volume when surrounding adenosine phosphates 
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This is perhaps surprising as the glycine-rich loop is generally believed to 
be highly flexible because of the displacement observed in crystal 
structures at pHs lower than 6 (Hemmer et al, 1997; Sachsenheimer & 
Schulz, 1977). However, this glycine becomes fixed in position upon 
staurosporine binding. The well-conserved position of this glycine, for 
75% of the non-redundant staurosporine complexes, but not for adenine 
complexes, suggests that the staurosporine leads to an induced fit or 
conformational selection in the kinases upon binding.  
2.3.5 The frequently occurring atoms obtained by superposing the 
domain 
When superposing neighbouring environments onto domain templates, I 
hypothesised that the residues that occur most frequently are the most rigid 
parts of the domain resulting from atoms that move in the same direction 
and with the same magnitude. The resulting amino acid residues from the 
N-terminal domain are not surprising. More than half of the 44 structures 
have their main chain sp3 carbons (28 structures) and nitrogens (25 
structures) nearby Ala 70 confined within a single element of the 1 Å grid 
(Figure 19). Both of these main chain atoms precede Ala 70 which acts as 
the ceiling of the pocket (Figure 20). Furthermore, the side chain of Val 57 
which locked the adenine ring into place is presented as the most 
frequently occurring from the residue array (Figure 20). 
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 Ala 70
Figure 19. Blue surfaces are atoms that frequently retain their positions from the domain 
superposition using the N-terminal domain of CDK2 as a template. The template’s helix 
is in red and sheets are in yellow. Ala70 is in yellow stick. 
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Figure 20. N-terminal domain superposition reveals the frequently occurring atoms and 
residues, with occupancies in brackets, from the total of 44 superposed structures. 
The picture obtained from C-terminal domain superposition is more 
complicated. The side chain and the main chain of Asp 166 are among the 
most populated entities in the array (Figure 22). This residue is neither 
buried nor part of a helix or sheet. It appears that this aspartate interacts 
with a conserved His 125 in the CDK2 template, i.e. Tyr 164 in PKA, 
which is located just under the DFG loop (Figure 22). In addition, the beta 
carbon of Trp 221 often retains its position because it is next to the 
invariant Asp 220 that acts to stabilize the catalytic loop by hydrogen 
bonding to the backbone amides of, again, Tyr 164 at a few positions 
preceding the beginning of the catalytic loop. These frequently occurring 
atoms and residues support the idea that the catalytic loop is actually rigid. 
If it can move, it should move in the same way as the C-terminal domain 
that is used as the template for superposition. The most conserved residue 
is Gly 225, which locates in the middle of the helix, perhaps as a result of 
the superposition process.  
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DFG loop 
Figure 21. Blue surfaces are atoms that frequently retain their position from the domain 
superposition using the C-terminal of CDK2 as a template. The DFG loop is shown in 
yellow stick. 
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Figure 22. C-terminal domain superposition illustrates conservation of both main chain 
and side chain of PKA equivalent residue Asp 166 and Gly 225, and beta carbon of 
residue Trp 221 which is equivalent to CT (26) of Ile in this CDK2 structure. The 
frequently occurring atoms are in spheres and frequently occurring residues are in dots, 
with occupancies in brackets, from the total of 44 superposed structures. 
2.4 Conclusion 
The representation of conserved atoms portrays the rigidity of structural 
units within the ATP binding pocket as well as those distant from the 
pocket. Both the hinge region and the catalytic loop serve as crucial 
scaffolds conserving the positions of residues through the evolution of 
protein kinases. Representations of conserved residues demonstrate that 
there are adaptations of the ATP binding pocket upon ligand binding and 
that staurosporine causes an induced fit of the GXGXXGX motif. These 
subtle differences are observable when comparing the frequently occurring 
neighbouring residues of ATP with those of staurosporine. The 
generalisations do not conform to the general belief that the glycine rich 
loop and the catalytic loop are flexible. When the structures of kinases 
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bound with either adenosine phosphate or staurosporine are superposed on 
a template of the N-terminal lobe, Ala 70 in the middle of the lobe retains 
its position. Alanine does not have strongly electrostatic side-chain features 
and it is interesting to know that it is held in a very precise position in the 
middle of this very labile secondary structure, the N-terminal lobe of the 
kinase. Furthermore, using all the large helices in the C-terminal lobe as 
the template showed that the catalytic loop was held in place with support 
from the helix in subdomain IX. From this approach, both the glycine rich 
loop and the catalytic loop have very precise locations. It is tempting to 
believe that in kinases with ligand bound, these two loops move with the 
secondary structure rather than swinging around. 
However, this is a difficult concept to prove because the method relies very 
much on the part of the structures that are chosen as templates. It also 
depends on the superposition algorithm which atoms the program prefers 
to align with the template.  
The next problem worth investigating is the peculiar spatial conservation 
of the penultimate atoms, which retain their positions in the C-terminal 
lobe superposition. The spatial arrangement of these atoms in the active 
site using atoms either at the penultimate or the end of the residues may 
give interesting clues about the basis of inhibitor selectivity. 
45 
C h a p t e r  3  
3 SHAPE COMPARISON OF THE ATP BINDING SITE 
The positions of residue clusters are exploited to define the shape of the 
ATP binding site in protein kinases and to monitor the expansion and 
contraction of the pocket between different kinases and on ligand binding. 
Kinases with a similar spatial arrangement of residues have been shown to 
bind to a similar set of inhibitors. An analysis of the correlation of distance 
matrices demonstrates that there is no relationship between the similarity 
in amino acid sequence and the similarity in the spatial arrangement of the 
side chains in the pocket. On the other hand, kinases with high similarity in 
the spatial arrangement of the side chains tend to bind a similar set of 
inhibitors.  
3.1 Introduction 
Current global protein structure classification schemes such as CATH and 
SCOP do not adequately underpin drug discovery because they do not 
provide information about binding site similarities (Debe & Hambly, 
2004). In principle such information should give clues to potential targets 
and mechanisms of action, so assisting the design of selective therapeutic 
compounds (Jacoby, 2006). In this chapter, I explore the possibility of 
relating sequence and structural information to the ability to bind a ligand. 
Initially, I investigate whether kinases with similar binding site amino acid 
sequences tend to have the same binding affinities for a particular ligand. 
Secondly, I employ a novel shape comparison method to see whether 
kinases with similar shapes of their adenine binding site pockets have the 
same binding characteristics. Finally, I analyse dendrograms derived from 
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both sequence and structural features to define relationships with real 
experimental binding data.  
My shape comparison method relies on estimating correlations between 
distance matrices using the Mantel test, where the distances are measured 
from the representative, mostly penultimate, atoms of the residues. The 
challenge arises from the fact that the distances in the matrices are not 
independent of each other: changing the position of one object would 
change the distance from that object to each of the others. Therefore, the 
relationship between two matrices cannot be assessed by evaluating the 
correlation coefficient and testing its statistical significance. The classical 
Pearson correlation coefficient is used for measuring the correlation 
between the matrices, and the significance of this statistic is assessed by 
comparison with the distribution found by randomly reallocating the order 
of the elements in one of the matrices many times (Bonnet & Peer, 2002). 
Therefore, this procedure can overcome the problems arising from the 
statistical dependence of elements within each of the two matrices. 
3.2 Method 
3.2.1 Dataset  
The preliminary data sets used for residue selection were those structures 
from the PDB with IDs indicating ‘protein kinase activity’, i.e. those with 
gene ontology ID GO:0004672 in the MSDlite database (Golovin et al, 
2004). These PDB IDs were filtered through the PISCES server (Wang & 
Dunbrack, 2003) to select a protein chain based on resolution, R-factor and 
completeness.  
3.2.2 Kinase catalytic domain superposition and alignment 
The eighty chosen chains with resolutions better than 3.0 Å and R-factors 
less than 0.30 were then superposed onto the cyclic AMP dependent 
protein kinase (PKA) structure (PDB ID: 1STC, chain E) using the 
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program Baton based on the method developed in Comparer (Sali et al, 
1990). The details of their quality and the complex crystallised are listed in 
Appendix A. 
3.2.3 Distance matrices construction 
The obtained structural alignment in format (.ali) was used to infer 
equivalent residues in the kinase superfamily using the program 
KinaseMap (Smith, 2006). Distances between every residue surrounding 
the pocket were measured from representative atoms in distinctive parts of 
the amino acids near the end of the side chains (see Table 4). Half-diagonal 
distance matrices were constructed for each PDB chain in the dataset. 
3.2.4 Matrix correlation and dendrogram construction 
The correlations between the matrices were calculated by the Mantel test 
using program zt (Bonnet & Peer, 2002). The relationships between 
distance matrices were defined using the neighbour-joining algorithm from 
the program PHYLIP (Felsenstein, 2004). The sequences of the catalytic 
domains and also the residues in the active sites were aligned in order to 
calculate dendrograms for comparison with the shape-based dendrogram 
using program ClustalX. The dendrograms were made using the program 
TREEVIEW (Page, 1996).  
3.2.5 Circular dendrogram construction 
The equivalent set of distances was also measured for a new set of 35 non-
redundant crystal structures of kinases, which have been assayed by Fabian 
et al. (Fabian et al, 2005). These structures are the PDB files with the best 
resolutions that have the protein names matching those assayed by Fabian 
et al. and contain a variety of inhibitors bound in the ATP binding site. 
This allows the relationship between the spatial arrangement of residues of 
different kinases and their binding affinities (Kd) against 10 ligands to be 
visualised. The colour gradient representation of the tree plotting program 
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iTOL (Letunic & Bork, 2007) was used where the intensity of the colours 
was proportional to –log10Kd in order to allow comparison for millimolar to 
sub-nanomolar values of binding constants (Kd). 
3.3 Results & Discussion 
3.3.1 Residue selection for the construction of quasi-shape 
I wish to investigate whether the spatial arrangement of residues in the 
ATP binding pocket has an influence on which inhibitor the kinase 
recognises. In order to avoid comparing extremely variable regions of the 
pocket, I focused only on protein structures with staurosporine or adenine-
ring containing compounds bound. A set of seven points was selected that 
can represent common features of the pocket. The Mantel test can 
distinguish the pockets of different kinases based on the assumption that 
the matrix of distances between points surrounding the adenosine pocket 
can reflect key features of the pocket shape in multiple dimensions; I call a 
matrix of this sort a “quasi-shape” (Figures 23 & 24).  
 
Figure 23. The quasi-shape is located between the N-terminal and the C-terminal lobes 
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 Figure 24. The quasi-shape (purple lines) 
Calculated correlation coefficients among distance matrices of the same 
size and order of elements can be used to estimate the similarities in the 
spatial arrangements of side chains and hence the relationship between 
shape and the ability of the parent kinase to bind various inhibitors. The 
resulting shape-based dendrogram is constructed from 17 points in 17 
residues, which are equivalent to the following residues in cAMP 
dependent protein kinase: Leu 49, Gly 50, Val 57, Ala70, Met 71, Lys 72, 
Val 104, Met 120, Glu 121, Tyr 122, Val 123, Glu 170, Asn 171, Thr 183, 
Asp 184, Glu 127, Leu 173. 
These residues can be found in the multiple structural alignment in the 
JOY format (Mizuguchi et al, 1998) in Figure 26. 
 
Figure 25. JOY annotations. 
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Figure 26. Multiple alignments from superposition of the kinases using program Baton. 
 
3.3.2 Dendrogram constructed from the quasi-shape 
The result suggested that Mantel test correlations between the matrices 
derived from a small set of inter-atomic distances, between 7 frequently 
occurring atoms, can separate the majority of staurosporine complexes 
from the adenine containing complexes (Figure 27). This means there are 
observable differences in spatial arrangement of these atoms when 
staurosporine and adenine are bound. Thus, the Mantel Test appears to 
work well for classifying different three dimensional geometric shapes. 
However, the same kinase in different crystal forms can be scattered 
throughout the resulting shape-based dendrogram, implying that 
similarities between these conserved atoms are not sufficient to 
differentiate the structures of kinases (Figure 27).  
Therefore, I investigated the use of distinctive parts near the ends of each 
amino acid residue as the centres for distance measurements in the 
construction of the distance matrices, thus allowing the derivation of a 
quasi-shape from each PDB file. The choice of these atoms, which depends 
on their residue type, is shown in Figure 11. By gradually increasing the 
number of residue points, I was able to categorise the same kinase in 
different crystal forms and different complexes into the same branch of the 
dendrogram. This dendrogram places the same type of kinase in different 
complexes in the same branch regardless of the bound ligand, and the 
staurosporine binding structures were clustered into one half of the tree 
(Figure 28). Therefore, the constructed matrices appear to be able to 
represent similar pockets.  
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 Figure 27. Mantel test can distinguish the shape derived from 7 frequently occurring 
atoms in staurosporine complex from adenosine phosphate complex, but structures of 
the same kinase, e.g. KAPCA are scattered throughout the tree. 
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Figure 28. The shape-based dendogram constructed from 17 points in 17 residues, which 
places the same type of kinase in different complexes in the same branch regardless of 
the bound ligand. 
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3.3.3 Sequence relationship with inhibitor binding 
I next investigated the relationship between the similarity obtained from 
sequence alignment and the ligand selectivity. However, it is difficult to 
conclude from these dendrograms whether the whole domain sequence 
alignment (Figure 29), the ligand accessible region alignment (Figure 30), 
or the shape similarity (Figure 31) dendrogram is better because these 
dendrograms cannot represent that very weak binding is somewhat similar 
to not binding at all. Hence, I also produced circular dendrograms using 
gradient colour to represent the relationship between sequence and shape to 
the binding affinities to 10 inhibitors so that the binding can be compared 
by the intensity of the colour.  
 
Figure 29. Phylogenetic tree obtained from neighbour joining clustering of Baton’s structural sequence alignment of the whole kinase domain. The first 
column is the PDB ID, the next twenty columns are inhibitors from supplementary information 4 of Fabian et al., and the final column is the kinase name. 
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Figure 30. Phylogenetic tree obtained from neighbour joining clustering of Baton’s structural alignment of residues in the ligand accessible region (closer 
than 3Å from any part of the ligand from 14 non-redundant human kinases)  
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 Figure 31. Phylogenetic tree obtained from neighbour joining clustering of Mantel’s correlation of distance matrices 
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3.3.4 Dendrogram displaying the relationship between shape and 
inhibitor binding affinities 
The general sequence-based dendrogram (Figure 32) is shown for 
comparison with the shape comparison dendrogram (Figure 33). It can be 
seen that kinases with similar sequence does not always bind similar 
inhibitors. 
 
TK 
 
Figure 32. The classic dendrogram based on sequence similarity from structure based 
sequence alignment using the program Baton. The intensity of the colour is proportional 
to -log10Kd of the inhibitor. The kinases with closest quasi-shape similarity are marked 
with arrows. 
STE 
CAMK 
AGC 
CMGC 
64 
When I apply the same dendrogram colouring method to the set of 35 non-
redundant structures where the Kd of the enzyme has been studied by 
Fabian et al. (Fabian et al, 2005), I obtain a dendrogram that characterises 
the ability to bind ten ligands, based on the similarity in quasi-shape as 
shown below (Figure 33).  
 
 
Figure 33. The shape-based dendrogram shows the matrix correlation between the 
shapes of the kinases and their binding affinities to 10 inhibitors. The kinases with 
closest quasi-shape similarity are marked with arrows. 
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It is evident that kinases with similar pocket quasi-shapes can have similar 
inhibitor binding profiles, regardless of their family membership. A nice 
example is serine/threonine kinase 10 (STK10), which is clustered in the 
sequence-based dendrogram (Figure 32) as an STE kinase as defined in the 
protein kinase phylogenetic tree by Manning et al. (Manning et al, 2002). 
When considering STK10 in terms of similarity in spatial arrangement of 
residues (Figure 33), it is instead paired with leukocyte-specific protein 
tyrosine kinase (LCK) which is a tyrosine kinase. The sequences are quite 
different, but the quasi-shapes of these pockets are the most similar in this 
dendrogram and their abilities to bind seven inhibitors are very similar. 
Many kinases with similar sequences, for example CDK2 and CDK5 or 
DAPK2 and DAPK3, also have very similar quasi-shapes and inhibition 
profiles. This quasi-shape-based dendrogram provides a way of visualising 
relationships among kinases, complementing that of the classical sequence-
based dendrogram. My dendrogram (Figure 33) demonstrates that the 
similarity in quasi-shape can sometimes explain the ability to bind a set of 
ligands regardless of the overall sequence identity.  
3.3.5 A case study: BUB1 kinase 
I illustrate the use of this method with a homology model of BUB1 kinase. 
The information I used to construct the dendrogram is based on the 
information about the shape from a homology model alone. The shape of 
the BUB1's active site was compared with 37 non-redundant kinase 
structures. The method employs the centre point of 17 active site residues 
to construct the distance matrices for each kinase and then to find the 
correlation between them. The homology model of BUB1 appears to have 
highest similarity with CLK1. If one discards all the tyrosine kinases, it is 
apparent that CLK1, DAPK2, DAPK3, and PIM1 appear to be in the same 
group in the quasi-shape classification. 
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There is evidence from a study by the Structural Genomics Consortium 
(Marsden & Knapp, 2008) that a class of imidazo-pyridazine inhibitors 
which binds to CLK1, PIM1 and DAPK3 shows selectivity against a panel 
of 40 Ser/Thr kinases. PIM1 and CLK1 share only 18% sequence identity 
but they appear in the same branch of the shape-based dendrogram if 
tyrosine kinases are not considered. Therefore, my quasi-shape analysis is 
useful for selecting kinases which share similarity in the shape of the 
adenine binding pocket. Since BUB1 appears in the shape based 
dendrogram to be in the same branch as CLK1, PIM1, DAPK2, and 
DAPK3, an inhibitor of BUB1 might be designed by using a CLK1 
inhibitor with alteration in electrostatic properties to suit BUB1. 
 
Figure 34. BUB1 and its similarity to other kinase with available inhibition constants. 
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3.4 Conclusion 
For the kinase pairs which show highest similarity in their quasi-shape, 
STK10 and LCK, there is a correlation between the similarity in the quasi-
shape of the pocket and the ligand selectivity. An experimental analysis of 
CLK1, PIM1 and DAPK3 suggests that my novel shape comparison 
method is able to distinguish kinases which bind to the same compound. 
The method may be useful for predicting the binding characteristics of 
kinases of unknown structure, as illustrated in this chapter for the BUB1 
kinase domain. However, in order to understand the determinants of 
inhibitor selectivity, the electrostatic properties of each amino acid cannot 
be neglected. In the following chapter, I investigate this further in order to 
answer the question: Which residues in the active site influence how well 
the kinase can bind staurosporine?  
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C h a p t e r  4  
4 UNDERSTANDING INFLUENTIAL RESIDUES USING 
QUANTITATIVE STRUCTURE ACTIVITY 
RELATIONSHIPS 
A reverse pharmacophore approach. 
Amino acid residues in the active site that influence how well 
staurosporine can bind are investigated by a Multiple Linear Regression 
method. This approach resembles QSAR, the difference being that, instead 
of correlating the differences in functional groups of the ligand with the Kd 
of the same protein, the differences in the distances between all the side 
chains of different kinases are chosen in order to identify those that 
correlate with the Kd for staurosporine. A set of “influential” residues, 
where differences in spatial arrangement have been shown to affect the Kd 
tremendously, are obtained from the set of distances that have the highest 
correlation with the Kd. A phylogenetic tree built from these 13 influential 
residues alone can cluster the kinase inhibition profiles as successfully as 
the general sequence alignment phylogenetic tree. The QSAR equation can 
be interpreted as a preference for shorter or longer distances between 
these influential residues, and is shown to agree well with the Kd. Closure 
between the N-terminal and C-terminal lobe and a larger size of the 
gatekeeper residue promote tight binding to staurosporine. 
4.1 Introduction 
Staurosporine has very few strongly electrostatic features. Its major 
interactions with protein kinases are largely steric with non-polar groups. 
Thus, I hypothesised that the tightness of inhibitor binding might be 
determined by the compactness of residues in the pocket. In order to test 
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this idea and to predict binding affinities from the structures, I assumed 
that good binding requires certain geometric restraints and investigated 
which distance descriptors correlate well with the dissociation constants. 
For instance, if the distances are shorter for most of the structures with low 
binding constants, this would suggest that contraction along that direction 
is required for tight binding. The goal for this experiment is to predict 
binding affinities directly from structures. This approach resembles a 
Quantitative Structure Activity Relationship (QSAR), but all the input 
parameters are measured from the structure in terms of distances that 
constitute the quasi-shape of the ATP binding pocket.  
Although QSAR methodologies have been widely used in order to try to 
understand binding affinities through various parameters related to 
lipophilicity, charges and hydrogen bonding character, distances between 
certain atoms in the protein have not been used. Because the experimental 
data depend very much on the method and the experimentalist, I chose 
dissociation constants of staurosporine (Kd,STU) from Fabian et al. (Fabian 
et al, 2005) as the sole source of my experimental binding data. Structures 
in this training set have Kd,STU between 0.5 to 870 nM and both adenine-
containing or staurosporine-bound structures are considered. Adenine ring-
containing structures are included in the data set on the assumption that the 
rigid parts of the pockets that harbour adenosine or staurosporine share 
similar conformations and electronic features. The advantage of assuming 
that the structure of the adenosine phosphate-bound complex resembles the 
same enzyme in the staurosporine-bound complex is that there are more 
structures in complex with adenosine containing compounds. The greater 
number of structures with available Kd,STU values allowed me to test my 
equation by predicting Kd,STU for further kinase structures co-crystallised 
with adenine ring containing ligands. 
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4.2 Methods 
4.2.1 Dataset 
I filtered the Protein Data Bank (Berman et al, 2000) for X-ray structures 
of every kinase that Fabian et al. (Fabian et al, 2005) report a Kd for 
staurosporine (Kd,STU), and selected only structures which are co-
crystallised as either staurosporine or adenosine phosphate complexes.  
4.2.2 Distance selection 
As in the case of shape analysis, distances from 15 representative atoms 
between all non-gapped residues surrounding the pocket were measured 
and written out in the form of tab-delimited file. The calculated distances 
are coloured in a Microsoft Excel spreadsheet based on their values as 
follows. 
                        Minimum   <     Lower Tail    < Mean – S.D. 
 
                        Maximum   >    Upper Tail     > Mean + S.D. 
 
4.2.3 Multiple linear regression  
Multiple linear regression was performed using program XLSTAT 
(Fahmy, 2008) to find the best equation to relate the distances measured 
between the centre points near the end of the side chains (see Figure 11) 
and log10Kd,STU.  
4.2.4 Descriptor representation 
The distances shown to correlate with the binding affinities were drawn 
manually in the structure of PKA (PDB ID 1stc, chain E) by writing 
dummy atoms and specifying the connections between them. The file was 
visualised using the Pymol molecular visualisation program (DeLano, 
2002). 
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4.2.5 Circular dendrogram construction 
The relationships between 113 kinases in Fabian’s data set were drawn 
based on selections of some residues in the pocket using neighbour-joining 
clustering in ClustalX (Thompson et al, 1997). The dendrograms were 
produced with gradient colour representation using program iTOL (Letunic 
& Bork, 2007) in order to reflect the log10Kd values of the inhibitors, 
including: 
4.2.5.1 Clustering based on similarity of amino acid residues in contact 
with staurosporine and showing correlation (<-0.4 and > 0.4) 
with Kd,STU in the multiple linear regression analysis. The 
gatekeeper residues are shown on the outer circle of the 
dendrogram.  
4.2.5.2 Clustering based on similarity in the whole catalytic domain 
sequence. The tree was illustrated with data on the ability to 
bind inhibitors together with pictures of the catalytic domain of 
kinases from various families. 
4.2.5.3 Clustering based on equivalent amino acid residues which are 
within 3 Å distance from SB202190 in the crystal structure PDB 
ID 1PME with the binding affinities for SB202190  
(-log10Kd,SB202190) 
4.2.5.4 Clustering based on equivalent amino acid residues which are 
within 3 Å distance from SP600125 in the crystal structure PDB 
ID 1UKI with the binding affinities for SP600125  
(-log10Kd,SP600125) 
4.2.5.5 Clustering based on equivalent amino acid residues which are 
within 3 Å distance from Iressa in the crystal structure PDB ID 
2ITY with the binding affinities for Iressa (-log10Kd,Iressa) 
4.2.5.6 Clustering based on equivalent amino acid residues which are 
within 3 Å distance from LY333531 in the crystal structure PDB 
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ID 1UU3 and 2J2I with the binding affinities for LY333531  
(-log10Kd,LY333531) 
For the first two dendrograms, the selected inhibitors (i.e. staurosporine, 
LY-333531, SU11248, and ZD-6474) are amongst the most promiscuous 
ligand in the Fabian’s dataset. Therefore, the number of the kinases they 
can bind is sufficient to demonstrate trends in binding affinities. 
4.3 Results & Discussion 
I avoided including distances that are influenced by the type of ligand 
bound in the structure. This was achieved by discarding residue points that 
differ in position when found in contact with ATP or staurosporine. In this 
way I could be sure that the differences in distances were independent of 
whether staurosporine or ATP complexes are compared. The distances 
between pairs of 15 frequently occurring residues are chosen for Multiple 
Linear Regression. These distances are measured from the centres of the 
distinctive parts of residues that are equivalent to these residues in cAMP 
dependent protein kinase (PKA). 
Point 01: LEU 49 Point 02: GLY 50 
Point 03: VAL 57 Point 04: ALA70 
Point 05: MET 71 Point 06: LYS 72 
Point 07: VAL 104 Point 08: MET 120 
Point 09: GLU 121 Point 10: TYR 122 
Point 11: VAL 123 Point 12: GLU 170 
Point 13: ASN 171 Point 14: THR 183 
Point 15: ASP 184 
Table 5. Distances between pairs of 15 frequently occurring residues chosen for Multiple Linear Regression. 
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The aim was to select distances from the quasi-shape defined by 15 points 
in contact with staurosporine (Table 5), where the points correlate with the 
binding affinities either positively or negatively. Multiple linear regression 
was used for this task and the equations produced are shown in Table 6. 
Kd,STU is the dissociation constant of staurosporine, and the distance 
between residues X and Y is written as DX_Y. 
Table 6. Equations correlating the influential distances with log10Kd,STU 
Random 
Test 
R2 training R2 test set Equation 
None 0.6 - 
Equation 4: 
log10Kd,STU=3.4+0.1D50_184–0.4D120_123 
5 structures 0.6 0.7 
Equation 5: 
log10Kd,STU=3.4+0.1D50_184–0.4D120_123 
10 structures 0.7 0.7 
Equation 6: 
log10Kd,STU=3.6+0.1D50_184–0.4D120_123 
 
I tested the predictive power of these equations by leaving out randomly 
selected test sets. While the purpose of using multiple linear regression in 
this context was simply to select the set of distances that correlate well 
with the binding affinities, the resulting equations suggest that predictive 
power might be demonstrated if a larger dataset were available. All 
resulting equations appear to contain the same best sets of distances 
producing R2 values for the random test sets of about 0.7 for both 
equations (Figures 35 & 36).  
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Figure 35. The predictive power of the multiple linear regression equations, tested by 
leaving out 5 randomly selected test sets, shows R2 about 0.7. 
Test set random 10 structures
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Figure 36. The predictive power of the multiple linear regression equations, tested by 
leaving out 10 randomly selected test sets, shows R2 about 0.7. 
The distance descriptors which correlate well with binding affinities, either 
having positive or negative influence on Kd,STU, are called the ‘influential 
distances’. Figure 37 illustrates these influential distances in the structure 
of cyclic AMP dependent protein kinase (PKA), PDB ID 1stc. The 
residues that are used as the points of measurement for these influential 
distances can be used to describe how the position of their representative 
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atoms near the end of the side chains can influence Kd,STU. From all the 
equations shown in Table 6, the distance between residues 50 and 184, 
described in the equation as D50_184, is directly proportional to the value of 
log10Kd,STU, and the distance between residues 120 and 123, D120_123, is 
inversely proportional to log10Kd,STU. The meaning of the equation is that in 
kinases that are tightly bound to staurosporine, i.e. have a small 
log10Kd,STU, there is a preference for a smaller D50_184 and a larger D120_123.  
 
Figure 37. Interpretation of the multiple linear regression analysis shows that smaller 
values of Kd,STU result from the larger size of side chains of the gatekeeper and 
gatekeeper+3 residues, i.e. PKA equivalent residue: Met120 and Val123 (orange bar). The 
equation suggests that the closer approach between Gly50 of the N-terminal lobe and 
Asp184 of the C-terminal lobe (purple bar) correlate with tighter binding to staurosporine. 
In cAMP dependent protein kinase (PKA), the distance between residues 
50 and 184 is measured between the Cα of Gly50 of the GXGXXG motif in 
the N-terminal lobe to the Cγ of Asp184 of the DFG loop in the C-terminal 
lobe. Staurosporine is located between the two lobes, and the closer 
approach of these two motifs in a direction perpendicular to the plane of 
staurosporine reflects the better binding affinities presumably because of 
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the resultant tighter binding. In contrast, increasing the distance between 
residue 120 (gatekeeper) and 123 (gatekeeper+3) implies an expansion of 
the pocket along this direction. The equation suggests that these two 
residues should move further apart to accommodate staurosporine. The 
gatekeeper residue points toward the plane of staurosporine, while the 
gatekeeper+3 residue is located under the indolocarbazole ring. The size of 
the gatekeeper and the gatekeeper+3 residues may have a key role in 
locking the lactam in the correct orientation while making optimal steric 
interactions with the indolocarbazole of staurosporine. The larger size of 
the gatekeeper residue likely results in the larger distance and correlates 
with good binding because the larger volumes of the side chains in the 
plane of the lactam ring promote favorable hydrophobic interactions in the 
pocket. 
Thirteen residues which are in contact with staurosporine and show 
correlation (<-0.4 and > 0.4) with Kd,STU were selected for the clustering of 
staurosporine binding affinities. These residues are equivalent to PKA 
residues 49, 50, 57, 70, 71, 72, 120, 121, 122, 123, 170, 171, and 184. In 
Figure 38, the resulting dendrogram constructed by the neighbour-joining 
algorithm of the thirteen residues is combined with data on the ability to 
bind staurosporine from Fabian et al. (Fabian et al, 2005) in order to 
investigate whether the similarities between these influential residues 
would result in similar binding constant. The resulting dendrogram can 
cluster tight staurosporine binders into two major groups with obviously 
better binding affinities (Figure 38). I also display the gatekeeper residues, 
which in Figure 38 lie beside the affinities of staurosporine. It can be seen 
that the majority of staurosporine tight binders have large gatekeeper 
residues, e.g. Phe and Met at the position equivalent to PKA residue 120 
(Figure 38). Smaller gatekeeper residues, e.g. Thr or Leu, tend to be 
associated with weaker binding affinities to staurosporine.  
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 Figure 38. A dendrogram displaying relationships between 113 kinases based on 
neighbour joining of the 13 residues that are highly correlated to binding constants. 
Most kinases with better binding affinities to staurosporine (dark red) have large 
gatekeeper residues, e.g. phenylalanine (F), methionine (M). A majority of kinases 
which are inhibited by ZD-6474 (blue) has threonine (T) or valine (V) as a gatekeeper 
residue. Binding affinities to LY-333531 (green) and SU11248 (yellow) are shown for 
comparison. 
The dendrogram produced from the whole catalytic domain sequence 
alignment was made for comparison. It is clear that the similarity in 
sequence of the whole catalytic kinase domain does not imply that the 
enzyme would bind to the same set of inhibitors (Figure 39). It is 
interesting that the ability to cluster ZD-6474 in the thirteen active site 
residue dendrogram is even better than the whole domain clustering. 
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 CDK2                                                                  PKA 
SRC                                                                                   PHKG1 
INSR                                                  PAK 
Figure 39. The binding affinities to promiscuous inhibitors, staurosporine (red), LY-
333531(green), SU11248 (yellow), and ZD-6474 (blue), demonstrate that the similarity 
in sequence cannot predict the ability to bind inhibitor. 
A further question that I address is whether there is any other inhibitor for 
which the active site residues can be used to distinguish good binders from 
poor binders. The similarities in ligand accessible residues of four 
promiscuous inhibitors where there are available crystal structures in 
complex with kinases show that we cannot predict the trend in binding 
affinities in this way. All of these inhibitors are more selective than 
staurosporine. This is probably because the inhibition by these inhibitors is 
governed by fewer residues. Other factors, such as the flexibility of the 
ligand, the electrostatic potential, and the steric interaction in the pocket 
might make sequence comparison of active site residues inadequate for the 
prediction of binding affinities. 
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Figure 40. Dendrogram constructed from alignment of residues within SB202190 
accessible region 
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Figure 41. Dendrogram constructed from alignment of residues within SP600125 
accessible region 
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Figure 42. Dendrogram constructed from alignment of residues within Iressa accessible 
region 
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Figure 43. Dendrogram constructed from alignment of residues within LY333531 
accessible region 
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4.4 Conclusion 
I have dissected the contribution to kinase staurosporine binding affinities 
in terms of distances between residues that line the ATP binding site. I 
have proposed that the size of the gatekeeper and closure of the pocket 
together affect the tightness of staurosporine binding. Here I have shown 
using the three-dimensional structures of kinases that larger sizes of 
gatekeeper residues normally result in tighter binding to staurosporine. 
This is probably a result of the compactness caused by the larger volumes 
of the side chains in the plane of the lactam ring which result in a better 
fitting of staurosporine. The closure of the DFG loop and the glycine rich 
loop also correlates to the tightness of staurosporine binding. The 
clustering of kinases based on 13 influential residues also shows that the 
ability to bind staurosporine can be grouped roughly based on similarity of 
a few residues in the pocket. However, this method of clustering cannot be 
applied to more selective inhibitors. The amount of selectivity determining 
residues selected for these inhibitors for the construction of the dendrogram 
is not optimal, and more detailed comparison is required for each inhibitor 
to understand the basis of each inhibitor’s selectivity. 
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C h a p t e r  5  
5 UNDERSTANDING CROSS-REACTIVITY BASED ON 
COMMON SUBSTRUCTURES 
A web application, MAHORI (http://www-cryst.bioc.cam.ac.uk/mahori), 
has been developed to query atomic interaction information from the 
protein-ligand database Credo (http://camelot.bioc.cam.ac.uk/drupal/ 
databases/credo). When the query has been made by submitting a SMILES 
string, drawing the chemical functional group or typing the compound’s 
name, the website can then display all the crucial interactions that a 
molecule makes with proteins in the PDB. A simple search query for 
staurosporine showed that the greater the number of the hydrogen bond 
and ionic interactions made by the methyl amine moiety, the better the 
binding affinity to staurosporine. This information can be useful in 
identifying selectivity-determining residues. 
5.1 Introduction 
Crystal structures serve as templates for many facets of drug discovery 
(Breitenlechner et al, 2005). A survey of the market value of small-
molecule drugs has shown that two-thirds of the sales resulted from 
analogue designs (Wermuth, 2006). Understanding the interactions made 
by chemical analogues presented in the Protein Data Bank may therefore 
suggest synthetic strategies for lead optimisation. Nevertheless, gathering 
the binding characteristics of a particular analogue is time-consuming and 
there is no publicly available resource that facilitates this type of 
understanding. My web-based application, MAHORI, is acronymed from 
its function for Mapping Analogous Hetero-atoms onto Residue 
Interactions. It aims to provide visualisation and classification of molecular 
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interactions made by the user-query atoms obtained from the heterogen 
section of the PDB file (wwPDB, 2007). 
A few web resources allow PDB structures and their superpositions to be 
queried based on ligand structure, including Relibase (Bergner et al, 2001) 
and IsoStar (Bruno et al, 1997). Selection of amino acid residues that 
interact with a queried ligand can also be achieved by FireDB (Lopez et al, 
2007) and classification of ligand-protein interactions based on residue 
contacts can be obtained from MSDsite (Golovin et al, 2005). However, 
these websites do not allow for comparison of the molecular interactions of 
multiple structures at the level of ligand substructure. 
The rationale for allowing user-defined substructure comparisons is based 
on the idea of the bioisostere that often shares a similar number and 
position of interactions with the protein, such as hydrogen bonding 
environment. Selection of the analogous part of the molecule could give an 
indication of the significant interactions that the substructure can contribute 
to the binding. This chapter describes an approach to selecting either the 
atoms that comprise the equivalent substructure in several molecules which 
can relate to cross-reactivity amongst several kinases or non-carbon atoms 
that are likely to make significant interactions which are selective for a 
small set of kinases. 
5.2 Methods 
5.2.1 Rationale 
MAHORI supports robust querying of the Protein Data Bank through its 
underlying protein-ligand database, Credo (Schreyer & Blundell, 2009). 
This database stores all types of interactions and contact distances that the 
ligands make with the protein. This is achieved using a method adapted 
from assignment of interaction types described in the approach for 
optimising fragment and scaffold docking (Marcou & Rognan, 2007). 
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Every atom of the ligand and its contacting neighbour atoms have their 
pre-defined types and the distances are calculated for every interacting 
pair. By prioritising the types of atoms and the distances, the interaction 
types can be assigned for all atom pairs.  
5.2.2 Available query types 
The user can make a query by providing a chemical structure, a SMILES 
string (Weininger, 2002), a chemical name or a PDB three-letter code. The 
ligand’s PDB three-letter code is the main type of query which will lead to 
a substructure selection panel. When searching by the chemical name, the 
program will look for the ligand’s PDB three letter codes in the Credo 
database. When searching for a fragment, the program receives the query 
in the form of a chemical drawing from program MarvinSketch 4.1.12 
(ChemAxonLtd., 2007) and converts it to a SMILES string.  
 
Figure 44. The MAHORI web-interface allows for various forms of ligand query, e.g. 
by providing a chemical structure, a SMILES string, a chemical name or a PDB three-
letter code.   
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Once the SMILES string is obtained, the program obgrep from the 
OPENBABEL package (Banck et al, 2007) searches for the ligand which 
contains that string in the Protein Data Bank. This program will then write 
an output file containing a list of the ligand PDB three-letter codes.  
5.2.3 Query execution process 
For each ligand PDB three-letter code, the program will provide the user 
with a list of the atoms that constitute the ligand and the name of the 
proteins that interact with these ligands. The user can select atoms of 
interest from this list. The name of the protein will be provided based on 
the interacting partners of those atoms. The process goes on until the last 
ligand in the list. 
The program uses the set of ligand atoms obtained from the user to make a 
MySQL query for a list of interacting protein atoms. The contact distances 
and interaction type are provided by the Credo database. The program 
prints all interactions that this set of atoms make and populates the closest 
contact per residue into a table of residue interactions.  
 
Figure 45. Colour code used for displaying ligand-residue interactions in MAHORI 
5.2.4 Data presentation 
MAHORI returns the output interactions into two panels. The left panel is 
a molecular viewer which can display the molecular interaction using the 
program Jmol 11.3.42 (TheJmolDevelopmentTeam, 2007), where the user 
can view the molecule in several styles, e.g. wireframe, strands, cartoon, 
rocket. The right panel prints out the final table for each PDB file which 
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contains the interactions that are sorted amongst the protein atoms nearest 
to the ligand atoms. Interacting residues are displayed in colours according 
to the interaction type. Clicking the interacting residues in the right panel 
will trigger the picture of the interacting residues in the left panel. Multiple 
user-defined substructures can be retrieved and displayed in the same page.   
 
Figure 46. Example of MAHORI output displaying interaction made with N4′ of 
staurosporine. More details of N4′ interaction can be found in Figure 51. 
5.3 Results & Discussion 
5.3.1 Understanding staurosporine promiscuity  
The interactions found in common between all protein kinases and 
staurosporine can be dissected into those that are conserved involving the 
lactam and tetrahydropyran moieties and the steric/hydrophobic contacts 
made by the indolocarbazole ring.  
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 Figure 47. The potential group which likely causes alteration in binding affinities is the 
methylamine moiety of staurosporine. 
I speculated that interactions that were not identified in the previous QSAR 
study, involving the methyl amino (N4′) and the methoxy group (O3′) of 
staurosporine, could play roles in constraining the distance between the N- 
and C-terminal lobes to the optimal value.  
 
Figure 48. The chemical structure of staurosporine shows the position of N4′ used for 
MAHORI query. 
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These distances are neither constant in position so that they can be captured 
by the grid, nor a linear function of binding affinities that can be captured 
by multiple linear regression. More distances can be identified by 
incorporating quadratic terms into the multiple linear regression in the 
same way as the Hansch equation in Section 1.4. This equation is obtained 
from collaboration with Professor Amiram Goldblum, who performed the 
Hansch analysis and suggested that the best way to describe this system is 
by including the square term in the function. The equation that is obtained 
using this approach is as follows (Equation 7): 
Equation 7. 
log Kd,STU =  44.82 +  0.02 × (D104_122)2 - 0.26 × D120_122  
- 5.89 × D70_170 + 0.18 × (D70_170)2 +  0.25 × D71_170; 
 
where: Kd,STU is the dissociation constant of staurosporine, the distance 
between residues X and Y is written as DX_Y, and standard deviation (S.D.) 
= 0.28, R2 = 0.83, R = 0.91. 
The R2 is significantly better than the linear equation without the square 
terms. Although the R2 is higher, there is a trade off between the ability to 
explain the binding affinities and over-fitting which arises from using a 
larger number of descriptors. Therefore, I verified the equation with a test 
set of newly released structures in the PDB and the binding affinities of 
these structures were found to be predicted with high accuracy (Figure 49). 
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Figure 49. Multiple linear regression with the square distance terms (see equation 7). 
The navy-dots comprise the dataset from 38 kinases that are used to construct the 
equation. The non-navy dots are the test set of newly released structures from the 
Protein Data Bank (cyan, PDB ID 2hw7; green, PDB ID 2dq7; orange, PDB ID 2itq; 
magenta, PDB ID 2clq). 
 
Figure 50. The terms obtained from Equation 7 confirm the role of the size of the 
gatekeeper (D120_122) and the closure between the N-terminal and C-terminal lobe 
(D71_170). This equation also suggests an optimal distance along the direction between 
Ala 70 and Glu 170. 
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Equation 7 includes two distances in directions that were not present in the 
equations without square terms in Table 6. The first term is the distance 
D104_122 (purple bar between Y122 and V104 in Figure 50), linking 
residues that are found in the tight binding pocket and which should move 
closer together to act as tweezers that tighten the pocket around the lactam 
area. The second is the distance D70_170 (blue bar between Ala70 and 
Glu170 in Figure 50) which is a quadratic term in equation 7. This term 
implies that an optimal distance is required along the direction of the blue 
bar. The term D70_170 suggests a role for the distance along the direction 
that passes through the methylamine N4′ of staurosporine (Figure 50).  
Indeed, the hydrogen bonds or ionic interactions that staurosporine can 
make along this direction are associated with the major differences in the 
binding affinities.  
I found that the number of hydrogen bonds made by residues around N4′ of 
staurosporine corresponds well with the trend in binding affinity (Table 7). 
Kinase structures that have two residues making hydrogen bonds or ionic 
interactions to N4′ of staurosporine, i.e. CDK2, PKA, PIM1, and LCK, 
have binding affinities below 51 nM. Most structures that have only one 
residue contributing hydrogen bonds or ionic interactions to N4′ have 
binding affinities between 51-440 nM, i.e. CSK, EGFR, FYN, M3K5. The 
kinase STK16, which does not make any interaction with N4′, has a binding 
affinity of 200 nM.  
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Table 7. Number of interactions made by the kinases with methylamine (N4′) of 
staurosporine. 
Number of interactions Protein 
kinase 
PDB ID 
Kd, STU 
(nM) H-bond Ionic vdW 
CDK2 1AQ1 8.1 2 1 2 
PIM1 1YHS 15 2 1 2 
LCK 1QPJ 20 2 - 2 
PKA 1STC 50 1 1 2 
SYK 1XBC 7 1 - 1 
FYN 2DQ7 51 1 - 1 
M3K5 2CLQ 120 1 - 1 
CSK 1BYG 440 1 - 1 
MKNK2 2HW7 22 - - 1 
EGFR 2ITU 70 - 1 2 
STK16 2BUJ 200 - - - 
 
In order to achieve better affinity for kinases, the strategy might be to 
identify a residue in the protein close to the methyl amino (N4′) or to 
modify the staurosporine ligand so that it can make a further hydrogen 
bond. The reference PKA structure is the PDB ID: 1STC from Figure 51. 
The majority of kinases make one hydrogen bond with the atom that is 
equivalent to the main chain carbonyl oxygen of residue 170. When there 
are two hydrogen bonds made with N4′, the additional hydrogen bond 
comes from the side chain of Glu 127 (Figure 51). 
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 Figure 51. Interactions made by the atom N4′ of staurosporine in various crystal 
structures. The PDB code of the protein chain is shown in red and the name of the 
protein is in brackets. The interacting residues are highlighted with the name of the 
residue in square brackets followed by the residue number and the protein chain.  
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Therefore, I speculate that the binding affinities of staurosporine 
derivatives can be affected most by optimising the interaction with the side 
chains of residues that are equivalent to Glu 127 in PKA (Asp 86 in 
CDK2). The type of this residue varies between kinases but the position is 
aligned well with no insertion or gap in the Baton structural alignment 
(Figure 26). 
Making point mutations of active site residues in order to achieve a better 
binding affinity to staurosporine might also be achieved by altering  
Glu 127 of PKA to a residue that can make an optimal hydrogen bond to 
N4′ of staurosporine. This suggestion might be useful for finding a new 
kinase construct that binds better to staurosporine and may help in 
producing more proteins that would provide X-ray structures of 
staurosporine complexes. 
5.3.2 Understanding simple bioisosteric replacement for synthetic 
strategy 
According to a study on the bioisosteric similarity of molecules based on 
structural alignment and observed chemical replacement in drugs (Krier & 
Hutter, 2009), replacement of variable substructures in staurosporine can 
be considered in terms of the replacement of N4′, O3′, and their methyl 
substituents. Various bioisosteric substitutions can be found as in Table 8. 
For example, for a methoxy oxygen (OR or O3′ of staurosporine), more 
exchanges to methylene groups were observed than to fluorine atoms. 
From the list in Table 8, the methoxy group can be substituted with NHR 
or SR, and the amine group can be substituted with OR or =NR to preserve 
the size and ability to form hydrogen bond of the linker. Choices for 
methyl group replacement are more diverse but may lead to selectivity for 
a particular kinase. 
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 Table 8. Most common bioisosteric substitutions regarding one-to-one exchanges of 
atoms from Krier & Hutter.  
-OR 
(O3′) 
-NHR 
(N4′) -CH3 
-CH2- -CH2- Cl 
CH3 OR CH2R 
NHR =CR2 OR 
Car Car OH 
=CR2 Nar F 
NR2 =NR NH2 
Nar =NH Br 
OH  I 
SR   
F   
 
Once the desired kinase is chosen, MAHORI might be used to investigate 
the tendency of substituting the N4′ from the (-NHR) substitution column. 
In this way the binding affinities for a large set of kinases can be slightly 
modified and may lead to the design of an inhibitor which is selective for a 
smaller group of kinases. The possibility of this application depends on the 
amount of feature interactions available on the Protein Data Bank. 
5.3.3 Understanding promiscuous substructure of FGFR inhibitors 
I now analyse small molecules that target the FGFR TK in order to 
understand the similarity of the interactions they make. Four crystal 
structures of inhibitor-bound FGFR1 TK domains exist in the PDB (PDB 
IDs: 1AGW, 1FGI, 2FGI and 3C4F). The interactions made with the 
FGFR were investigated using MAHORI.  
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Substructure matching using MAHORI demonstrates that particular 
substructures of the FGFR inhibitor molecules are responsible for kinase 
promiscuity.  
 
Figure 52. The indolinone substructure (red circle) which binds to many kinases. 
The indolinone substructure of SU5402 and SU4984 (Mohammadi et al, 
1997) interacts with many kinases, such as CDK2 (1PF8, 2BHE, 2BHH, 
1KE5-1KE9, 1E9H, 1R78), PIM1 (1YXX), CDK5 (1UNH), GSK3B 
(1Q41, 1UV5), Casein Kinase 1 homolog1 (1EH4), Serine/Threonine-
protein kinase 12-A (2BFY), NEK2 (2JAV), CHK1 (2AYP), and STK10 
(2J7T). From the number of kinases that it binds and the position of the 
indolinone binding area, this substructure has the characteristic of a hinge 
binder which can be found from the web application MAHORI. 
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 Figure 53. Pyrido[2,3D]pyrimidinyl substructure (red circle) which binds many kinases 
as well as many dihydrofolate reductases  
The pyrido[2,3D]pyrimidinyl substructure of PD173074 (Mohammadi et 
al, 1998) also binds ABL1 (1M52, 1OPK, 1OPL, 2FO0, 2G2H), CDK6 
(2EUF) and many dihydrofolate reductase structures. The difference is the 
atom that is equivalent to N3 of the ligand PD173074 makes one hydrogen 
bond and one aromatic interaction with the hinge region of ABL1, while 
the same atom makes only an aromatic interaction without hydrogen 
bonding with a beta-strand in dihydrofolate reductase. This atom does not 
interact with protein at all in CDK6. This hinge binder substituent may be 
useful for the design of a multi-target drug, which aims to interfere with 
both DNA-synthesis via dihydrofolate reductase and signal transduction 
via kinases. 
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 Figure 54. 7-azaindole derivatives in the structure of FGFR from PDB ID 3C4F  
 
Figure 55. 7-azaindole from PDB ID 2UVX shows its ability to bind cAMP dependent 
protein kinase without having any decorating substituent, which may be useful as a 
scaffold for multi-target drug design. 
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The 1H-pyrrole[2,3-B]pyridine, or 7-azaindole, moiety binds several 
kinases, such as SRC (3EN4), CDK2 (3BHU) and CHK1 (1ZYS, 2QHM) 
amongst others. A crystal structure of this fragment alone bound to cyclic-
AMP dependent protein kinase (2UVX) implies that 7-azaindole is the 
promiscuous substructure (Figure 55). This substructure is another hinge 
binder which may be suitable as a scaffold for multi-target drug design. 
Decorating substituents should aim to achieve selectivity by limiting the 
number of kinases to which the molecule can bind. 
5.4 Conclusion 
I have learned that the numbers of hydrogen bonds and ionic interactions 
determine the magnitudes of binding affinities and the interactions made 
with methylamine are important to the binding with staurosporine. From 
this understanding, I can identify Glu 127 as the residue which can be used 
to achieve better binding affinities for staurosporine derivatives. 
Promiscuous scaffolds of the ligand can be found in the four examples of 
FGFR inhibitors which clearly demonstrate the part of the molecules that 
acts as a hinge binder. I show that three scaffolds which bind to FGFR can 
also bind to various other kinases. My web-tool, MAHORI, enables 
comparison of the amount, the type and the position of the interactions in 
one results page on the computer screen. This kind of information might be 
useful for rational drug design and medicinal chemistry education. 
The tool is useful to confirm the parts of ligands that bind to kinases non-
specifically and to rationalise the specificity determining residues. The 
findings may be helpful in guiding synthetic strategies and mutagenesis 
studies by narrowing down the choice of chemical group replacement in 
the ligand and amino acid substitutions in the kinase. 
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C h a p t e r  6  
CONCLUDING REMARKS AND FUTURE WORK 
At the time of starting the thesis, my research was geared towards the 
understanding of the determinants of inhibitor selectivity. However, due to 
the fact that there are so many conformations of kinases with many 
different kinds of inhibitors available in the Protein Data Bank, my 
research was refocused on those forms which allow comparisons of many 
structures; these are staurosporine and ATP complexes.  
The problem proved to be not so simple; Q-SiteFinder estimated the active 
site volumes in CDK2 alone could be hugely variable, for example 182 Å3 
(PDB ID 1aq1) with staurosporine and 406 Å3 (PDB ID 1fin) with ATP. 
This led to the idea of developing an algorithm to observe frequently 
occurring atoms, because some parts of the pocket that interact with the 
ligand were held in the same position regardless of their different volumes.  
By superposing the rigid parts of the ligands, the staurosporine complexes 
were proven to be good models. In contrast with ATP binding complexes, 
staurosporine complexes show a lack of plasticity in the pocket, especially 
in the constrained region. The superposed position of Gly 50, which varies 
in ATP complexes but which stays close to oxygen of the tetrahydropyran 
ring in staurosporine complexes, led to the induced fit hypothesis. The 
conservation of positions of atoms in the hinge regions for both complexes 
confirmed that this was the major determinant of cross-reactivity of 
inhibitors. 
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Domain superposition provided a new way to compare the rigid parts of 
the molecule. It became apparent that a residue in the lower middle part of 
the N-terminal lobe, Ala 70, positions the ligand in protein kinases. This 
approach could also correctly identify Asp 166 in the C-terminal lobe as a 
residue that is conserved in position. Interestingly Asp 166 is the amino 
acid residue which accepts the proton from the substrate and the reason 
why this region is called the catalytic loop. 
The concept of frequently occurring atoms was used further to consider the 
shape created by these unmoving points. I wanted to know which distance 
between these points are the most important. Although there is no 
correlation between distances and binding affinities when the distance 
between the static atoms is measured, when the distances between the side 
chains are considered, there is considerable improvement in the correlation 
with binding affinities. Hence, I developed the idea of measuring the 
distances between the ends of the side chains. 
QSAR indicated that the gatekeeper residue was always involved in the 
distances that gave rise to the best equations. This coincided with the 
observation that the size of the gatekeeper residue affects inhibitor binding. 
Another distance that was important was the one that passes through N4′ of 
staurosporine. Optimal distances along this direction could result in strong 
molecular interactions. The greater the number of hydrogen bond 
interactions and ionic interactions along this direction, the better the 
binding affinities. 
In theory, the MAHORI website could be developed to allow bottom-up 
fragment design. Indeed, one way to decide whether or not a fragment will 
stay in a pocket is by considering local environments in other protein 
crystal structures. Promiscuous scaffolds can also be identified which lead 
to knowledge about cross-reactivity between enzymes in different 
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pathways. However, at the time of conducting this research, drug-like 
substructures in the PDB were still quite rare. Hence, there was not much 
choice in substructure queries using MAHORI. I believe that when the 
Protein Data Bank grows, the website will become fruitful. There is room 
for improvement in MAHORI. The first priority is to allow water-mediated 
interactions. Then I would wish to develop a method to classify the 
environment and compile a list of frequent substructure interactions. It 
would be useful if the user could link substructures together to form a new 
ligand for a particular input pocket. 
My idea for future work on kinases is to develop further software for 
automated identification of specificity determining residues. I would define 
specificity as the features that are retained after subtracting the 
promiscuous ones from all those in a particular kinase. Therefore, 
observing promiscuous features by frequently occurring atoms can be a 
starting point for obtaining the specificity determining features. Identifying 
these residues would result in a clear benefit for kinase inhibitor design. 
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APPENDIX 
A. Details of protein kinase chains used for shape comparison. 
  Protein PDB Length Res(Å) R Species Ligand Others Kd,STU 
1 ACK1 1U54B 291 2.80 0.23 HUMAN ACP MG,PTR   
2 AKT2 1O6KA 336 1.70 0.20 HUMAN ANP MN,TPO   
3 CDK2 1AQ10 298 2.00 0.22 HUMAN STU   8.1 
  CDK2 1B38A 299 2.00 0.18 HUMAN ATP MG 8.1 
  CDK2 1B39A 299 2.10 0.20 HUMAN ATP MG 8.1 
  CDK2 1FINC 298 2.30 0.21 HUMAN ATP   8.1 
  CDK2 1GY3C 299 2.70 0.25 HUMAN ATP MG,TPO 8.1 
  CDK2 1JSTC 298 2.60 0.20 HUMAN ATP MN,TPO 8.1 
  CDK2 1QMZA 299 2.20 0.22 HUMAN ATP MG,TPO 8.1 
4 CHK1 1NVRA 289 1.80 0.19 HUMAN STU   30.0 
5 CK2A 1DAWA 327 2.20 0.22 MAIZE ANP MG   
6 CSK 1BYGA 278 2.40 0.20 HUMAN STU   440.0 
7 CSK21 1PJKA 334 2.50 0.19 HUMAN ANP     
  CSK21 1YMIA 334 1.66 0.19 HUMAN ANP     
8 CSK2A 1LP4A 332 1.86 0.21 MAIZE ANP MG   
9 DAPK1 1IG1A 294 1.80 0.19 HUMAN ANP MN   
  DAPK1 1JKKA 294 2.40 0.20 HUMAN ANP MG   
  DAPK1 1JKLA 294 1.62 0.20 HUMAN ANP     
10 EPHA2 1MQBA 333 2.30 0.24 HUMAN ANP   870.0 
11 EPHB2 1JPAA 312 1.91 0.23 MOUSE ANP     
12 FAK1 1MP8A 281 1.60 0.19 HUMAN ADP     
13 FUS3 2B9FA 353 1.80 0.21 YEAST ADP MG   
  FUS3 2B9IA 353 2.50 0.20 YEAST ADP MG   
  FUS3 2B9JA 353 2.30 0.20 YEAST ADP MG   
  FUS3 2B9HA 353 1.55 0.19 YEAST ADP MG,STE7   
14 GCN2 1ZY5A 303 2.00 0.23 YEAST ANP MG   
  GCN2 1ZYDA 303 2.75 0.21 YEAST ATP MG   
15 GSK3B 1J1BA 420 1.80 0.22 HUMAN ANP     
  GSK3B 1J1CA 420 2.10 0.22 HUMAN ADP MG   
  GSK3B 1PYXB 422 2.40 0.21 HUMAN ANP MG   
  GSK3B 1Q3DA 424 2.20 0.23 HUMAN STU     
16 IF2A 2A19B 284 2.50 0.23 YEAST ANP MG   
17 IGF1R 1JQHA 308 2.10 0.20 HUMAN ANP MG   
  IGF1R 1K3AA 299 2.10 0.21 HUMAN ACP PTR   
18 INSR 1I44A 306 2.40 0.21 HUMAN ACP MG 73.0 
  INSR 1IR3A 306 1.90 0.19 HUMAN ANP MG,PTR 73.0 
19 ITK 1SM2A 264 2.30 0.25 HUMAN STU -   
20 KAPCA 1ATPE 350 2.20 0.18 MOUSE ATP MN 50.0 
  KAPCA 1BKXA 350 2.60 0.22 MOUSE ADE TPO 50.0 
  KAPCA 1FMOE 350 2.20 0.18 MOUSE ADN TPO 50.0 
  KAPCA 1JBPE 350 2.20 0.17 MOUSE ADP TPO 50.0 
  KAPCA 1L3RE 350 2.00 0.20 MOUSE ADP MG,TPO 50.0 
  KAPCA 1Q24A 350 2.60 0.20 BOVINE ATP MG,TPO 50.0 
  KAPCA 1RDQE 350 1.26 0.13 MOUSE ADP,ATP MG,TPO 50.0 
  KAPCA 1STCE 350 2.30 0.21 BOVINE STU   50.0 
  KAPCA 1U7EA 350 2.00 0.17 MOUSE ANP MN,TPO 50.0 
21 KIT 1PKGA 329 2.90 0.23 HUMAN ADP MG,PTR 100.0 
22 KPCT 1XJDA 345 2.00 0.20 HUMAN STU     
23 KSYK 1XBCA 291 2.00 0.25 HUMAN STU   7.0 
24 LCK 1QPCA 279 1.60 0.20 HUMAN ANP PTR 20.0 
  LCK 1QPDA 279 2.00 0.20 HUMAN STU   20.0 
  LCK 1QPJA 279 2.20 0.21 HUMAN STU   20.0 
25 MAPK2 1NXKA 400 2.70 0.24 HUMAN STU     
  MAPK2 1NY3A 400 3.00 0.27 HUMAN ADP     
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26 MP2K1 1S9JA 341 2.40 0.25 HUMAN ATP MG   
27 PDPK1 1H1WA 289 2.00 0.20 HUMAN ATP     
  PDPK1 1OKYA 310 2.30 0.22 HUMAN STU     
  PDPK1 2BIYA 310 1.95 0.19 HUMAN ATP     
28 PHKG1 1QL6A 298 2.40 0.24 RABBIT ATP MN 0.5 
  PHKG1 2PHKA 277 2.60 0.25 RABBIT ATP MN 0.5 
29 PIM1 1XR1A 300 2.10 0.27 HUMAN ANP MG 15.0 
  PIM1 1YHSA 273 2.15 0.23 HUMAN STU   15.0 
  PIM1 1YI4A 273 2.40 0.21 HUMAN ADN   15.0 
  PIM1 1YXTA 293 2.00 0.18 HUMAN ANP   15.0 
  PIM1 1YXUA 293 2.24 0.23 HUMAN AMP   15.0 
  PIM1 2BZKB 313 2.45 0.19 HUMAN ANP   15.0 
30 PKNB 1O6YA 299 2.20 0.19 MYCTU ACP MG   
31 Q9JLS3 1U5RA 348 2.10 0.21 RAT ATP MG   
32 SKY1 1Q8YA 373 2.05 0.21 YEAST ADE,ADP MG   
  SKY1 1Q97A 373 2.30 0.21 YEAST ATP ADN,MG   
  SKY1 1Q99A 373 2.11 0.22 YEAST ANP     
33 SRPK1 1WBPA 397 2.40 0.23 HUMAN ADP     
34 STK16 2BUJA 317 2.60 0.19 HUMAN STU   200.0 
35 STK6 1MQ4A 272 1.90 0.23 HUMAN ADP MG 16.0 
  STK6 1MUOA 297 2.90 0.26 HUMAN ADN   16.0 
  STK6 1OL5A 282 2.50 0.19 HUMAN ADP MG,TPO 16.0 
  STK6 1OL6A 282 3.00 0.28 HUMAN ATP   16.0 
  STK6 1OL7A 282 2.75 0.26 HUMAN ADP MG,TPO 16.0 
  STK6 2C6DA 275 2.20 0.23 HUMAN ANP   16.0 
36 ZAP70 1U59A 287 2.30 0.22 HUMAN STU     
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